10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2013

OR

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from____ to ____

Commission File Number: 001-32295

ADHEREX TECHNOLOGIES INC.

(Exact Name of Registrant as Specified in Its Charter)

Canada (State or Other Jurisdiction of Incorporation or Organization	20-0442384 (I.R.S. Employer Identification No.)
PO Box 13628, 68 TW Alexander Drive Research Triangle Park, North Carolina (Address of Principal Executive Offices)	27709 (Zip Code)

Registrant's Telephone Number, Including Area Code: (919) 636-4530

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES x NO ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes þ No¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer  ¨		Accelerated File   ¨
Non-Accelerated Filer    ¨	(Do not check if smaller reporting company)	Smaller reporting company   x

Indicated by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).YES ¨NO x

As of August 10, 2013, there were 25,157,861 shares of Adherex Technologies Inc. common stock outstanding.

TABLE OF CONTENTS

	Page
PART I: FINANCIAL INFORMATION
Item 1.  Financial Statements (unaudited)	3
Unaudited Interim Consolidated Balance Sheets –June 30, 2013 (Unaudited) and December 31, 2012	3
Unaudited Interim Consolidated Statements of Operations –For the three Months and Six Months Ended June 30, 2013 and 2012	4
Unaudited Interim  Consolidated Statements of Cash Flows –For the three Months and Six Months Ended June 30, 2013 and 2012	5
Unaudited Interim  Consolidated Statements of Stockholders' Equity-For the Period Ended September 3,1996 to June 30, 2013	6
Notes to Unaudited Interim Consolidated Financial Statements	10
Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3.  Quantitative and Qualitative Disclosures about Market Risk	20
Item 4.  Controls and Procedures	21
PART II: OTHER INFORMATION	22
Item 1. Legal Proceedings	22
Item 1A.  Risk Factors	22
Item 2. Unregistered Sales of Equity Securities	23
Item 3. Defaults Upon Senior Securities	23
Item 4. Mine Safety Disclosure	24
Item 5. Other Information	24
Item 6.  Exhibits	24
Signatures	25

2

PART 1: FINANCIAL INFORMATION

Item 1. Financial Statements

Adherex Technologies Inc.

(a development stage company)

Unaudited Interim Consolidated Balance Sheets

(U.S. Dollars and shares in thousands)

	June 30, 2013			December 31, 2012
Assets
Current assets:
Cash and cash equivalents	$	1,007		$	2,303
Prepaid expenses		20			56
Other current assets		3			6
Total assets		1,030			2,365
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable		716			259
Accrued liabilities		65			423
Derivative liabilities		2,678			6,640
Total liabilities		3,459			7,322
Commitments (see Note 6)
Stockholders' equity:
Common stock, no par value; unlimited shares authorized; 25,158 shares issued and outstanding (2012-25,158)		65,952			65,952
Additional paid-in capital		38,420			38,391
Deficit accumulated during development stage		(108,044	)		(110,543	)
Accumulated other comprehensive income		1,243			1,243
Total stockholders’ equity (deficiency)		(2,429	)		(4,957	)
Total liabilities and stockholders’ equity	$	1,030		$	2,365

(The accompanying notes are an integral part of these unaudited interim consolidated financial statements)

3

Adherex Technologies Inc.

(a development stage company)

Unaudited Interim Consolidated Statements of Operations

(U.S. Dollars and shares in thousands, except per share amounts)

	Three Months Ended						Six Months Ended						Cumulative From September 3, 1996 to
	June 30, 2013			June 30, 2012			June 30, 2013			June 30, 2012			June 30, 2013
Revenue	$	-		$	-		$	-		$	-		$	-
Operating expenses:
Research and development		554			860			732			1,157			69,900
Impairment of capital assets		-			-			-			-			386
Gain on deferred lease inducements		-			-			-			-			(497	)
Acquired in-process research and development		-			-			-			-			13,094
General and administrative		373			390			732			710			32,826
Total operating expenses		927			1,250			1,464			1,867			115,709
Loss from operations		(927	)		(1,250	)		(1,464	)		(1,867	)		(115,709	)
Other income (expense):
Settlement of Cadherin litigation		-			-			-			-			(1,283	)
Interest expense		-			-			-			-			(19	)
Unrealized/realized gain on derivatives		7,535			645			3,962			3,971			7,219
Other income		2			-			2			-			261
Interest (loss)/income and other		(3	)		3			(1	)		8			2,896
Total other income (expense), net		7,534			648			3,963			3,979			9,074
Net income/(loss) and total comprehensive income / (loss)	$	6,607		$	(602	)	$	2,499		$	2,112		$	(106,635	)
Basic and diluted net income /(loss) per common share	$	0.26		$	(0.02	)	$	0.10		$	0.08
Weighted-average number of common shares outstanding, basic		25,158			25,158			25,158			25,158
Weighted-average common shares outstanding, diluted		25,639			25,158			25,714			25,158

(The accompanying notes are an integral part of these unaudited interim consolidated financial statements)

4

Adherex Technologies Inc.

(a development stage company)

Unaudited Interim Consolidated Statements of Cash Flows

(U.S. Dollars and shares in thousands, except per share amounts)

	Three Months Ended						Six Months Ended						Cumulative From September 3,
	June 30, 2013			June 30, 2012			June 30, 2013			June 30, 2012			1996 to June 30, 2013
Cash flows (used in):
Operating activities:
Net income/(loss)	$	6,607		$	(602	)	$	2,499		$	2,112		$	(106,635	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		-			-			-			-			1,404
Non-cash Cadherin Biomedical Inc. litigation		-			-			-			-			1,187
Unrealized gain on derivative		(7,535	)		(645	)		(3,962	)		(3,971	)		(7,219	)
Amortization of deferred lease inducements		-			-			-			-			(412	)
Unrealized foreign exchange loss		-			-			-			-			36
Loss on impairment of capital assets		-			-			-			-			386
Non-cash severance		-			-			-			-			168
Stock-based compensation - consultants					35						35			1,048
Stock-based compensation - employees		29			17			29			17			10,298
Acquired in-process research and development		-			-			-			-			13,094
Changes in non-cash working capital		10			62			138			96			312
Net cash used in operating activities		(889	)		(1,133	)		(1,296	)		(1,711	)		(86,333	)
Investing activities:
Purchase of capital assets		-			-			-			-			(1,440	)
Disposal of capital assets		-			-			-			-			115
Proceeds from sale of assets		-			-			-			-			24
Release of restricted cash		-			-			-			-			190
Restricted cash		-			-			-			-			(209	)
Purchase of short-term investments		-			-			-			-			(22,148	)
Redemption of short-term investments		-			-			-			-			22,791
Investment in Cadherin Biomedical Inc.		-			-			-			-			(166	)
Acquired intellectual property rights		-			-			-			-			(640	)
Net cash used in investing activities		-			-			-			-			(1,483	)
Financing activities:
Conversion of long-term debt to equity		-			-			-			-			68
Long-term debt repayment		-			-			-			-			(65	)
Capital lease repayments		-			-			-			-			(8	)
Issuance of units, net of issue costs		-			-			-			-			86,443
Registration expense		-			-			-			-			(465	)
Proceeds from convertible note		-			-			-			-			3,017
Other liability repayments		-			-			-			-			(87	)
Financing expenses		-			-			-			-			(544	)
Security deposits received		-			-			-			-			35
Proceeds from exercise of stock options		-			-			-			-			51
Net cash provided by financing activities		-			-			-			-			88,445
Effect of exchange rate on cash and cash equivalents														378
(Decrease)/Increase  in cash and cash equivalents		(889	)		(1,133	)		(1,296	)		(1,711	)		1,007
Cash and cash equivalents - Beginning of period		1,896			4,719			2,303			5,297			-
Cash and cash equivalents - End of period	$	1,007		$	3,586		$	1,007		$	3,586		$	1,007

(The accompanying notes are an integral part of these unaudited interim consolidated financial statements)

5

Adherex Technologies Inc.

(a development stage company)

Unaudited Interim Consolidated Statements of Stockholders' Equity (Deficiency)

(U.S. dollars and shares in thousands, except per share information)

	Common Stock					Non-redeemable Preferred Stock		Additional Paid-in			Accumulated Other Comprehensive		Deficit Accumulated During Development			Total Stockholders’ Equity
	Number(Note 4)			Amount		of Subsidiary		Capital			Income		Stage			(Deficiency)
Balance at September 3, 1996		-		$	-	$	-	$	-		$	-	$	-		$	-
Issuance of common stock		89			-		-		-			-		-			-
Net loss		-			-		-		-			-		(37	)		(37	)
Balance at June 30, 1997		89			-		-		-			-		(37	)		(37	)
Net loss		-			-		-		-			-		(398	)		(398	)
Balance at June 30, 1998		89			-		-		-			-		(435	)		(435	)
Exchange of Adherex Inc. shares for Adherex Technologies Inc. shares		(89	)		-		-		-			-		-			-
Issuance of common stock		239			1,615		-		-			-		-			1,615
Cumulative translation adjustment		-			-		-		-			20		-			20
Net loss		-			-		-		-			-		(958	)		(958	)
Balance at June 30, 1999		239			1,615		-		-			20		(1,393	)		242
Issuance of common stock		16			793		-		-			-		-			793
Issuance of equity rights		-			-		-		171			-		-			171
Issuance of special warrants		-			-		-		255			-		-			255
Settlement of advances:
Issuance of common stock		16			175		-		-			-		-			175
Cancellation of common stock		(7	)		-		-		-			-		-			-
Cumulative translation adjustment		-			-		-		-			16		-			16
Net loss		-			-		-		-			-		(1,605	)		(1,605	)
Balance at June 30, 2000		264			2,583		-		426			36		(2,998	)		47
Issuance of common stock:
Initial Public Offering (“IPO”)		74			5,727		-		-			-		(38	)		5,689
Other		5			341		-		-			-		-			341
Issuance of special warrants		-			-		-		1,722			-		-			1,722
Conversion of special warrants		30			1,977		-		(1,977	)		-		-			-
Issuance of Series A special warrants		-			-		-		4,335			-		-			4,335
Conversion of Series A special warrants		69			4,335		-		(4,335	)		-		-			-
Conversion of equity rights		4			171		-		(171	)		-		-			-
Cumulative translation adjustment		-			-		-		-			182		-			182
Net loss		-			-		-		-			-		(2,524	)		(2,524	)
Balance at June 30, 2001		446			15,134		-		-			218		(5,560	)		9,792
Cumulative translation adjustment		-			-		-		-			11		-			11
Net loss		-			-		-		-					(3,732	)		(3,732	)
Balance at June 30, 2002		446			15,134		-		-			229		(9,292	)		6,071

(The accompanying notes are an integral part of these unaudited interim consolidated financial statements)

(continued on next page)

6

Adherex Technologies Inc.

(a development stage company)

Unaudited Interim Consolidated Statements of Stockholders' Equity (Deficiency) (Continued)

(U.S. dollars and shares in thousands, except per share information)

	Common Stock					Non-redeemable Preferred Stock			Additional Paid-in			Accumulated Other Comprehensive			Deficit Accumulated During Development			Total Stockholders’ Equity
	Number(Note 4)		Amount			of Subsidiary			Capital			Income			Stage			(Deficiency)
Balance at June 30, 2002		446		15,134			-			-			229			(9,292	)		6,071
Common stock issued for Oxiquant acquisition		446		11,077			-			543			-			-			11,620
Exercise of stock options		1		4			-			-			-			-			4
Distribution to shareholders		-		-			-			-			-			(158	)		(158	)
Stated capital reduction		-		(9,489	)		-			9,489			-			-			-
Stock options issued to consultants		-		-			-			4			-			-			4
Equity component of June convertible notes		-		-			-			1,058			-			-			1,058
Financing warrants		-		-			-			53			-			-			53
Cumulative translation adjustment		-		-			-			-			(159	)		-			(159	)
Net loss		-		-			-			-			-			(17,795	)		(17,795	)
Balance at June 30, 2003		893		16,726			-			11,147			70			(27,245	)		698
Stock options issued to consultants		-		-			-			148			-			-			148
Repricing of warrants related to financing		-		-			-			18			-			-			18
Equity component of December convertible notes		-		-			-			1,983			-			-			1,983
Financing warrants		-		-			-			54			-			-			54
Conversion of June convertible notes		96		1,216			-			(93	)		-			-			1,123
Conversion of December convertible notes		60		569			-			(398	)		-			-			171
Non-redeemable preferred stock		-		-			1,045			-			-			-			1,045
December private placement		640		8,053			-			5,777			-			-			13,830
May private placement		259		6,356			-			2,118			-			-			8,474
Exercise of stock options		1		23			-			-			-			-			23
Amalgamation of 2037357 Ontario Inc.		44		660			(1,045	)		363			-			-			(22	)
Cumulative translation adjustment		-		-			-			-			(219	)		-			(219	)
Net loss		-		-			-			-			-			(6,872	)		(6,872	)
Balance at June 30, 2004		1,993		33,603			-			21,117			(149	)		(34,117	)		20,454
Stock options issued to consultants		-		-			-			39			-			-			39
Stock options issued to employees		-		-			-			604			-			-			604
Cost related to SEC registration		-		(493	)		-			-			-			-			(493	)
Acquisition of Cadherin Biomedical Inc.		37		1,252			-			-			-			-			1,252
Cumulative translation adjustment		-		-			-			-			1,392			-			1,392
Net loss – six months ended December 31, 2004		-		-			-			-			-			(6,594	)		(6,594	)
Balance at December 31, 2004		2,030		34,362			-			21,760			1,243			(40,711	)		16,654

(The accompanying notes are an integral part of these unaudited interim consolidated financial statements)

(continued on next page)

7

Adherex Technologies Inc.

(a development stage company)

Unaudited Interim Consolidated Statements of Stockholders' Equity (Deficiency) (Continued)

(U.S. dollars and shares in thousands, except per share information)

	Common Stock					Non-redeemable Preferred Stock		Additional Paid-in		Accumulated Other Comprehensive		Deficit Accumulated During Development			Total Stockholders’ Equity
	Number (Note 4)		Amount			of Subsidiary		Capital		Income		Stage			(Deficiency)
Balance at December 31, 2004		2,030		34,362			-		21,760		1,243		(40,711	)		16,654
Financing costs		-		(141	)		-		-		-		-			(141	)
Exercise of stock options		1		25			-		-		-		-			25
Stock options issued to consultants		-		-			-		276		-		-			276
July private placement		337		7,060			-		1,074		-		-			8,134
Net loss		-		-			-		-		-		(13,871	)		(13,871	)
Balance at December 31, 2005		2,368		41,306			-		23,110		1,243		(54,582	)		11,077
Stock options issued to consultants		-		-			-		100		-		-			100
Stock options issued to employees		-		-			-		491		-		-			491
May private placement		431		5,218			-		822		-		-			6,040
Net loss		-		-			-		-		-		(16,440	)		(16,440	)
Balance at December 31, 2006		2,799		46,524			-		24,523		1,243		(71,022	)		1,268
Stock options issued to consultants		-		-			-		59		-		-			59
Stock options issued to employees		-		-			-		2,263		-		-			2,263
February financing		4,209		17,842			-		5,379		-		-			23,221
Exercise of warrants		116		563			-		131		-		-			694
Net loss		-		-			-		-		-		(13,357	)		(13,357	)
Balance at December 31, 2007		7,124		64,929			-		32,355		1,243		(84,379	)		14,148
Stock options issued to consultants		-		-			-		88		-		-			88
Stock options issued to employees		-		-			-		2,417		-		-			2,417
Net loss		-		-			-		-		-		(13,600	)		(13,600	)
Balance at December 31, 2008		7,124		64,929			-		34,860		1,243		(97,979	)		3,053
Stock options issued to consultants		-		-			-		10		-		-			10
Stock options issued to employees		-		-			-		355		-		-			355
Net loss		-		-			-		-		-		(3,012	)		(3,012	)
Balance at December 31, 2009		7,124		64,929			-		35,225		1,243		(100,991	)		406
Stock options issued to consultants		-		-			-		53		-		-			53
Stock options issued to employees		-		-			-		2,439		-		-			2,439
April financing		13,337		-			-		-		-		-			-
Net loss		-		-			-		-		-		(7,824	)		(7,824	)
Balance at December 31, 2010		20,461		64,929			-		37,717		1,243		(108,815	)		(4,926	)

The accompanying notes are an integral part of these unaudited interim consolidated financial statements)

(continued on next page)

8

Adherex Technologies Inc.

(a development stage company)

Unaudited Interim Consolidated Statements of Stockholders' Equity (Deficiency) (Continued)

(U.S. dollars and shares in thousands, except per share information)

	Common Stock				Non-redeemable Preferred Stock of		Additional Paid-in		Accumulated Other Comprehensive		Deficit Accumulated During Development			Total Stockholders’ Equity
	Number (Note 4)		Amount		Subsidiary		Capital		Income		Stage			(Deficiency)
Balance at December 31, 2010		20,461		64,929		-		37,717		1,243		(108,815	)		(4,926	)
Stock options issued to consultants		-		-		-		20		-		-			20
Stock options issued to employees		-		-		-		129		-		-			129
Rights offering		4,697		1,023		-		199		-		(1,250	)		(28	)
Net income		-		-		-		-		-		4,685			4,685
Balance at December 31, 2011		25,158		65,952		-		38,065		1,243		(105,380	)		(120	)
Stock options issued to consultants		-		-		-		152		-		-			152
Stock options issued to employees		-		-		-		174		-		-			174
Net loss		-		-		-		-		-		(5,163	)		(5,163	)
Balance at December 31, 2012		25,158		65,952		-		38,391		1,243		(110,543	)		(4,957	)
Net loss		-		-		-		-		-		(4,108	)		(4,108	)
Balance at March 31, 2013		25,158		65,952		-		38,391		1,243		(114,651	)		(9,065	)
Stock options issued to employees		-		-		-		29		-		-			29
Net income		-		-		-		-		-		6,607			6,607
Balance at June 30, 2013		25,158		65,952		-		38,420		1,243		(108,044	)		(2,429	)

(The accompanying notes are an integral part of these unaudited interim consolidated financial statements)

9

1. Going Concern

Adherex Technologies Inc. (“Adherex”), a British Columbia corporation together with its wholly-owned subsidiaries Oxiquant, Inc. (“Oxiquant”) and Adherex, Inc., both Delaware corporations, and Cadherin Biomedical Inc. (“CBI”), a Canadian corporation, collectively referred to herein as the “Company”, is a development stage biopharmaceutical company with a portfolio of product candidates under development for use in the treatment of cancer. With the exception of Adherex Inc., all subsidiaries are inactive.

These unaudited interim consolidated financial statements have been prepared using generally accepted accounting principles (“GAAP”) in the United States (“U.S.”) of America that are applicable to a going concern which contemplates that Adherex will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company is a development stage company and during the six months ended June 30, 2013 generated net income of $2,499 which includes an unrealized non-cash gain of $3,962 on derivative liabilities. Cash used in operations in the six months ended June 30, 2013 was $1,296. At June 30, 2013, the Company had an accumulated deficit of $108,045 and had experienced negative cash flows from operations since inception in the amount of $86,333.

These circumstances cast substantial doubt as to the ability of the Company to meet its obligations as they come due and, accordingly, the use of accounting principles applicable to a going concern may not be appropriate. The Company will need to obtain additional funding in the future in order to finance its business strategy beyond the current trials through the issuance of equity, debt or collaboration. If the Company fails to arrange for sufficient capital on a timely basis, it may be required to curtail its business activities until it can obtain adequate financing.

If we cannot obtain adequate funding in the future, we might be required to further delay, scale back or eliminate certain research and development studies, consider business combinations or even shut down some, or all, of our operations. It is management’s intent to continue operating the company until the results of the Phase III Children’s Oncology Group STS trial is finalized, which is expected to occur in the third quarter of 2013. The results of this trial will determine whether the company has any strategic alternative to an orderly wind-down.

These unaudited financial statements do not reflect the potentially material adjustments in the carrying values of assets and liabilities, the reported expenses, and the balance sheet classifications used, that would be necessary if the going concern assumption were not appropriate.

2. Significant Accounting Policies

Basis of presentation

The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. GAAP and are the responsibility of the Company’s management. These financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. Accordingly, these unaudited interim consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and notes filed with the Securities and Exchange Commission (“SEC”) in the Company's Annual Report on Form 10-K for the year ended December 31, 2012. The Company's accounting policies are consistent with those presented in the audited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012. These unaudited interim consolidated financial statements have been prepared in U.S. dollars.

Use of estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Significant estimates include certain accruals, valuation of derivative warrant liability and the value of stock based compensation. Actual results could differ from those estimates.

In the opinion of management, these unaudited interim consolidated financial statements include all normal and recurring adjustments, considered necessary for the fair presentation of the Company’s financial position at June 30, 2013, and to state fairly the results for the periods presented. The most significant estimates included in these financial statements are the derivative instruments described in Note 3. There were significant changes in their valuation during the quarter.

10

Newly Accounting Pronouncements Adopted

In February 2013, the FASB issued ASU No. 2013-02, "Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income" ("ASU 2013-02"), which requires companies to provide information about the amounts reclassified out of AOCI by component. In addition, companies are required to report significant amounts reclassified out of AOCI by the respective line items of net income if the amount reclassified is required to be reclassified to net income in its entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, companies are required to cross-reference to other disclosures that provide additional detail on those amounts. ASU 2013-02 is effective prospectively for reporting periods beginning after December 15, 2012 and has not impacted the Company's consolidated financial condition, results of operations or cash flows.

Cash and cash equivalents

Cash and cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less. The Company places its cash and cash equivalents in investments held by financial institutions in accordance with its investment policy designed to protect the principal investment. At June 30, 2013, the Company had $913 in money market investments, which typically have minimal risk and $94 in cash of which $13 was in Canadian dollars. The Company has not experienced any loss or write down of its money market investments.

3. Derivative Instruments

Effective January 1, 2009, the Company adopted Accounting Standards Codification (ASC) Topic 815-40, "Derivatives and Hedging" (ASC 815-40). One of the conclusions reached under ASC 815-40 was that an equity-linked financial instrument would not be considered indexed to the entity's own stock if the strike price is denominated in a currency other than the issuer's functional currency. The conclusion reached under ASC 815-40 clarified the accounting treatment for these and certain other financial instruments. ASC 815-40 specifies that a contract would not be treated as a derivative if it met the following conditions: (a) indexed to the Company's own stock; and (b) classified in stockholders' equity in the Company's statement of financial position. The Company's outstanding warrants denominated in Canadian dollars are not considered to be indexed to its own stock because the exercise price is denominated in Canadian dollars and the Company's functional currency is United States dollars. Therefore, these warrants have been treated as derivative financial instruments and recorded at their fair value as a liability. All other outstanding convertible instruments are considered to be indexed to the Company's stock, because their exercise price is denominated in the same currency as the Company's functional currency, and are included in stockholders' equity (deficiency).

The Company's derivative instruments include warrants to purchase 18,035 shares, the exercise prices for which are denominated in a currency other than the Company's functional currency, as follows:

· Warrants to purchase 13,337 shares at CAD $1.44 per whole share that expire on April 30, 2015; and

· Warrants to purchase 4,698 shares exercisable at CAD $1.44 per whole share that expire on March 29, 2016.

These warrants were recorded at their fair value as a liability at issuance and will continue to be re-measured at fair value as a liability at each subsequent balance sheet date. Any change in value between reporting periods will be recorded as unrealized gain/(loss). These warrants will continue to be reported as a liability until such time as they are exercised or expire. The fair value of these warrants is estimated using the Black-Scholes option-pricing model.

As of June 30, 2013, the fair value of the warrants expiring April 30, 2015 and March 29, 2016 was determined to be $1,729 and $898, respectively (December 31, 2012 – warrants expiring April 30, 2015 and March 29, 2016, fair value of $4,698 and $1,847, respectively), and the gain on these warrants for the three months ended June 30, 2013 was $5,286 and $2,147, respectively (For the three months ended June 30, 2012 - warrants expiring April 30, 2015 and March 29, 2016, gain of $513 and $125, respectively.) The six month gain on the warrants expiring April 30, 2015 and March 29, 2016 for the six months ended June 30, 2013 was $2,969 and $949, respectively (For the six months ended June 30, 2012 - warrants expiring April 30, 2015 and March 29, 2016, gain of $2,981 and $946, respectively.)There is no cash flow impact for these derivatives until the warrants are exercised. If these warrants are exercised, the Company will receive the proceeds from the exercise at the current exchange rate at the time of exercise.

11

Gain/(Loss) on Derivative Instruments	Three months ended June 30, 2013		Three months ended June 30, 2012
Warrants expiring April 30, 2015		5,286		513
Warrants expiring March 29, 2016		2,147		125
Options to contractors		102		7
Gain on Derivative Instruments		7,535		645

Gain/(Loss) on Derivative Instruments	Six months ended June 30, 2013		Six months ended June 30, 2012
Warrants expiring April 30, 2015	2,969		2,981
Warrants expiring March 29, 2016		949		946
Options to contractors		44		44
Gain on Derivative Instruments		3,962		3,971

During the fiscal year ended December 31, 2011, the Company issued 108 options to contractors with a Canadian dollar denominated strike price. Consequently, the Company now has derivatives relating to these options since the strike price is denominated in a currency other than the US dollar functional currency of the Company. While there is an exception to this rule for employees in ASU 2010-13 "Compensation-Stock Compensation (Topic 718):Effect of Denominating the exercise price of a share based payment award in the currency of the market in which the underlying equity security trades", no such exception exists for contractors. These options will be marked to market until the earlier of their expiry or exercise. The fair value of these options at June 30, 2013 was $51 (December 31, 2012 - $95) and the gain for the three and six months ended June 30, 2013 was $102 and $44, respectively (June 30, 2012 – gain of $7 and $44, respectively).

4. Stockholders' Equity

Warrants to purchase common stock

At June 30, 2013, the Company had the following warrants outstanding to purchase common stock priced in Canadian dollars with a weighted average exercise price of CAD $1.44 and a weighted average remaining life of 2.0 years:

Warrant Description	Common Shares Issuable Upon Exercise of Outstanding Warrants at June 30, 2013		Exercise Price In CAD Dollars		Expiration Date
Investor warrants (1)		13,337	$	1.44	April 30, 2015
Investor warrants (2)		4,698	$	1.44	March 29, 2016
		18,035

(1) On April 30, 2010, the Company announced that it had completed a first closing of a non-brokered private placement (“Private Placement”) of 240,066 units, at a price of CAD $0.03 per unit for net proceeds of CAD $7,200. Each unit consisted of one common share and one common share purchase warrant (a “Warrant”). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD $1.44 per whole share for a period of five years from the issue date.

(2) On March 29, 2011, the Company announced that it had completed a non-brokered rights offering of 84,559 units, at a price of CAD $0.03 per unit for total net proceeds of $2,547. Each unit consisted of one common share and one common share purchase warrant (a “Warrant”). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD $1.44 per whole share for a period of five years from the issue date.

12

Stock option plan

The Compensation Committee of the Board of Directors administers the Company’s stock option plan.  The Compensation Committee designates eligible participants to be included under the plan and approves the number of options to be granted from time to time under the plan. On June 24, 2010, at the Company’s annual meeting, shareholders approved an amendment to the Company’s Stock Option Plan (the “Plan Maximum Amendment”). The Plan Maximum Amendment relates to changing the maximum number of shares of common stock issuable under the Stock Option Plan from a fixed number of 20,000 to the number of shares that represent twenty five percent (25%) of the total number of all issued and outstanding shares of common stock from time to time.  On June 18, 2013, at the Company’s annual meeting, shareholders approved the continuation of the Plan Maximum Amendment for three more years until June 28, 2016. Based upon the current shares outstanding, a maximum of 6,290 options are authorized for issuance under the plan.  The option exercise price for all options issued under the plan is based on the fair value of the underlying shares on the date of grant.  All options vest within three years or less and are exercisable for a period of seven years from the date of grant.  The stock option plan, as amended, allows the issuance of Canadian and U.S. dollar grants.  During the three and six-month periods ended June 30, 2013 the Company recognized total stock-based compensation expense of $29 and $29. During the three and six-month periods ended June 30, 2012 the Company recognized total stock-based compensation expense of $52 and $52.

Valuation assumptions

The value of options granted in the three months ended June 30, 2013 and June 30, 2012, respectively were estimated using the Black-Scholes option-pricing model, using the following assumptions: expected dividend 0% and 0%, respectively; risk-free interest rate of 1.2-1.32% and 1.125 – 1.25%, respectively; expected volatility of 159-163% and 132-3%, respectively; and a 7 year expected life.

Stock option activity

The following is a summary of option activity for the six months ended June 30, 2013 for stock options denominated in Canadian dollars:

Options in thousands	Number of Options (thousands)		Weighted-average Exercise Price
Outstanding at December 31, 2012		4,171		CAD $ 0.78
Granted		-		-
Exercised		-		-
Expired		-		-
Outstanding at June 30, 2013		4,171		CAD $ 0.78

Canadian dollar denominated options issued to contractors vest immediately and are treated as derivative liabilities. They are recorded at fair value estimated using the Black Scholes model with the gain or loss reported as unrealized gain(loss).

The following is a summary of option activity for the six months ended June 30, 2013 for stock options denominated in U.S. dollars:

Options in thousands	Number of Options (thousands)		Weighted-average Exercise Price
Outstanding at December 31, 2012		1,327	$	0.67
Granted		35		0.86
Exercised		-		-
Expired		-		-
Outstanding at June 30, 2013		1,362	$	0.67

13

5. Fair Value Measurements

The Company has adopted the Fair Value Measurements and Disclosure Topic of the FASB. This Topic applies to certain assets and liabilities that are being measured and reported on a fair value basis. The Fair Value Measurements Topic defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosure about fair value measurements. This Topic enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The Topic requires that financial assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

Assets/Liabilities Measured at Fair Value on a Recurring Basis

	Fair Value Measurement at June 30, 2013
	Quoted Price in Active Markets		Significant Other		Significant
	for Identical Instruments		Observable Inputs		Unobservable Inputs
	Level 1		Level 2		Level 3		Total
Assets
Cash & Cash equivalents		94	$	913		-	$	1007
Liabilities
Derivative liabilities		-		2,678		-		2,678
TOTAL		94	$	3,591		-	$	3,685

The Company's financial instruments include cash and cash equivalents and derivatives. Only cash and cash equivalents and derivatives are carried at their fair value. The derivative liabilities include warrants denominated in a currency other than the Company’s functional currency and options issued to contractors in a currency other than the functional currency of the Company. The warrants are carried at fair value and calculated using the Black-Scholes option pricing model using the following assumptions: expected dividend 0%; risk-free interest rate of 1.21%-1.35%; expected volatility of 148% - 155%; and a 1.83 or 2.75 year remaining life. The options also use the Black-Scholes model with the following assumptions: expected dividend 0%; risk-free interest rate of 1.66%-1.78% expected volatility of 150%-152%; and a 4.4-4.9 year remaining life. The risk free rate was based on Bank of Canada Bond issues of similar term. Expected volatility was estimated by using historical volatility of weekly close share prices for a period equal to the remaining life of the instrument.

6. Commitments

The Company had no material commitments as of June 30, 2013.Under the service agreement with OCT Group LLC entered in August 2010, the Company was required to make several payments over the course of our Phase II clinical trial in Russia. The payments were made upon the fulfillment of several milestones during the clinical trial including regulatory approval of trial, enrollment of patients and the completion of therapy of patients. The Company amended the agreement in April 2011 and August 2011 for the addition of additional sites for OCT to service during the Phase II clinical trial. The Company amended the agreement in June 2012 for the transition to a paper-based database to be developed by OCT. In addition, the Company amended the agreement on October 29, 2012 for the addition of up to 20 patients to be enrolled. The service agreement with OCT expired on June 30, 2013.

Under the license agreement with Oregon Health & Science University (OHSU) for STS dated February 20, 2013, upon the first commercial sale of STS we may become responsible for a payment to OHSU of up to $0.1 million. Prior to this new license agreement with OHSU, the previous license agreement with OHSU dated September 26, 2002, included that the Company may have become responsible for a payment to OHSU of up to $0.5 million upon the successful completion of the Phase III clinical trial with COG or SIOPEL. The license agreement with OHSU dated September 26, 2002 was terminated on February 20, 2013. Royalty payments are contingent on sales.

In the event of his termination with us other than for cause, the Company will pay Rostislav Raykov $140 in severance. In the event of his termination with us other than for cause, the Company will pay Robert Andrade $140 in severance.

7. Subsequent Events

On August 1, 2013, Adherex settled a balance of $490 in accounts payables for a total of $230. This settlement is not reflected in the company’s financial statements for the period ending June 30, 2013.

14

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

CAUTIONARY STATEMENT

The discussion below contains forward-looking statements regarding our financial condition and our results of operations that are based upon our unaudited interim consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles, or GAAP in the United States (“U.S.”) and have been prepared by and are the responsibility of the Company’s management. The preparation of these consolidated financial statements requires our management to make estimates and judgments that affect the reported amounts of assets, liabilities, income and expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis. Our estimates are based on historical experience and on various other assumptions that we believe to be reasonable.

We operate in a highly competitive environment that involves significant risks and uncertainties, some of which are beyond our control. Our actual results, performance or achievements may be materially different from any results, performance or achievements expressed or implied by such forward-looking statements. Words such as “may,” “will,” “expect,” “might”, “believe,” “anticipate,” “intend,” “could,” “estimate,” “project,” “plan,” and other similar words are one way to identify such forward-looking statements. Forward-looking statements in this report include, but are not limited to, statements with respect to (1) our anticipated sources and uses of cash and cash equivalents; (2) our anticipated commencement dates, completion dates and results of clinical trials; (3) our efforts to pursue collaborations with the government, industry groups or other companies; (4) our anticipated progress and costs of our clinical and preclinical research and development programs; (5) our corporate and development strategies; (6) our expected results of operations; (7) our anticipated levels of expenditures; (8) our ability to protect our intellectual property; (9) the anticipated applications and efficacy of our drug candidates; (10) our ability to attract and retain key employees; and (11) the nature and scope of potential markets for our drug candidates. All statements, other than statements of historical fact, included in this report that address activities, events or developments that we expect or anticipate will or may occur in the future are forward-looking statements. We include forward-looking statements because we believe it is important to communicate our expectations to our investors. However, all forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties, including our need to raise money in the very near term and others as discussed in this report. Although we believe the expectations reflected in the forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be attained, and we caution you not to place undue reliance on such statements.

Overview

Adherex Technologies Inc. is a biopharmaceutical company focused on cancer therapeutics. We incorporated under the Canada Business Corporations Act (“CBCA”). At the Company's June 2011 Annual Meeting, shareholders of Adherex approved the continuation of Adherex Technologies’ federal incorporation under the CBCA to incorporation under the Business Corporations Act (British Columbia).We have three wholly-owned subsidiaries: Oxiquant, Inc. and Adherex, Inc., both Delaware corporations, and Cadherin Biomedical Inc., a Canadian company. Adherex's prioritization initiative focuses primarily on STS and Eniluracil.

STS is currently marketed for use in humans as part of a treatment for cyanide poisoning. We have licensed from Oregon Health & Science University intellectual property rights for the use of STS as a chemoprotectant, and are developing STS as a protectant against the hearing loss often caused by platinum-based anti-cancer agents in children. Preclinical and clinical studies conducted by Oregon Health & Science University and others have indicated that STS can effectively reduce the incidence of hearing loss caused by platinum-based anti-cancer agents. We have received Orphan Drug Designation in the United States for the use of STS in the prevention of platinum-induced ototoxicity in pediatric patients.

We are currently conducting Phase III trials of STS conducted by the International Childhood Liver Tumour Strategy Group, known as SIOPEL and the Children's Oncology Group. Each of these trials is managed by SIOPEL and the Children’s Oncology Group, respectively, and each group is responsible for the costs of the trial. We continue to hold STS patents and our responsibility in the testing is limited to providing the drug, drug distribution and pharmacovigilance, or safety monitoring, for the study. The SIOPEL trial is expected to enroll approximately 100 pediatric patients with liver (hepatoblastoma) cancer at participating SIOPEL centers worldwide and the Children's Oncology Group study was designed to enroll up to 135 pediatric patients worldwide in five different disease indications. The Company's Children Oncology Group study completed enrollment in the first half of 2012. The SIOPEL trial has enrolled 78 patients as of August 10, 2013. Final efficacy and safety data from the Children Oncology Group study is expected during the third quarter of 2013. If convincing efficacy and safety results are received from the Children's Oncology Group trial, Adherex plans to meet with the FDA to discuss a New Drug Application for STS.

15

Eniluracil was previously under development by GlaxoSmithKline. GlaxoSmithKline advanced eniluracil into a comprehensive Phase III clinical development program that did not produce positive results and GlaxoSmithKline terminated further development. We developed a hypothesis as to why the GlaxoSmithKline Phase III trials were not successful and licensed the compound from GlaxoSmithKline in July 2005. We believe that eniluracil might enhance and expand the therapeutic spectrum of activity of 5-FU, reduce the occurrence of a disabling side effect known as hand foot syndrome and allow 5-FU to be given orally. Adherex completed the enrollment of a Phase II trial comparing eniluracil/5-FU/leucovorin vs. capecitabine in metastatic breast cancer patients at the end of December 2012 after having enrolled 153 patients. After the completion of enrollment and with preliminary results of the Phase II trial, Adherex had an End-of-Phase 2 meeting with the FDA on May 22, 2013 to discuss the potential further development of eniluracil. During the FDA meeting, Adherex reviewed the opportunity that eniluracil offers to Metastatic Breast Cancer (MBC) patients who had rapid disease progression on capecitabine. Adherex proposed a small pivotal single arm clinical study addressing the special ability of eniluracil/5-FU/leucovorin to meet the medical needs of these patients. However, the FDA strongly recommended that Adherex consider other larger clinical trial design alternatives for the future development of eniluracil in MBC. Adherex management believes it would be in the best interests of shareholders and the cancer community to focus on seeking a partnership for eniluracil, which may include the Company evaluating viable indications for eniluracil other than MBC. Data from the Phase 2 trial will be submitted for publication in a scientific journal.

Our common stock trades on the OTCQB in the United States. Our common stock also trades on the Toronto Stock Exchange. The Toronto Stock Exchange has continuing listing standards, including minimum market capitalization and other requirements, that we might not meet in the future, particularly if the price of our common stock does not increase or we are unable to raise capital to continue our operations. On September 18, 2012, the Toronto Stock Exchange issued an official delisting review of our common stock. On January 7, 2013, the Toronto Stock Exchange completed its review of the Company and determined that the Company met TSX's continued listing requirements.

We have financed our operations since our inception on September 3, 1996 through the sale of equity and debt securities. We have not received and do not expect to have significant revenues from our product candidates until we are either able to sell our product candidates after obtaining applicable regulatory approvals or we establish collaborations that provide us with up-front payments, licensing fees, milestone payments, royalties or other revenue. We generated net income of approximately $2,499 for the six months ended June 30, 2013. The net income for the period ended June 30, 2013 was primarily as a result of a $3,962 unrealized non-cash gain on derivative liabilities, offset by operating expenses relating principally to the eniluracil Phase II clinical trial. As of June 30, 2013, our deficit accumulated during development stage was approximately $108,045.

Our filed Form 10-K for the year ended December 31, 2012 included a notation related to the substantial doubt of our ability to continue as a going concern. As a result of our limited financial resources, we have postponed or terminated many of our previously planned or ongoing clinical development programs. We currently plan to continue operations the company until the results of the Children’s Oncology Group Phase III STS trial is finalized, which is expected to occur in the third quarter of 2013. We are pursuing various strategic alternatives, including collaborations with other pharmaceutical and biotechnology companies. We believe that the results of the Phase III STS will impact the Company's ability to secure a transaction with a strategic partner. Our projections of our capital requirements are subject to substantial uncertainty. More capital than we had anticipated may be thereafter required. To finance our continuing operations we will need to raise substantial additional funds through either the sale of additional equity, the issuance of debt, the establishment of collaborations that provides us with funding, the out-license or sale of certain aspects of our intellectual property portfolio or from other sources. We might not be able to raise the necessary capital or such funding may not be available on acceptable terms. If we cannot obtain adequate funding in the future, we might be required to further delay, scale back or eliminate certain research and development studies, consider business combinations or even shut down some, or all, of our operations.

Our operating expenses will depend on many factors, including the progress of our drug development efforts and the implementation of further cost reduction measures. Our research and development expenses, which include expenses associated with our clinical trials, drug manufacturing to support clinical programs, salaries for research and development personnel, stock-based compensation, consulting fees, sponsored research costs, toxicology studies, license fees, milestone payments, and other fees and costs related to the development of product candidates, will depend on the availability of financial resources, the results of our clinical trials and any directives from regulatory agencies, which are difficult to predict. Our general and administrative expenses include expenses associated with the compensation of employees, stock-based compensation, professional fees, consulting fees, insurance, and other administrative matters associated with our corporate office in Research Triangle Park, North Carolina in support of our drug development programs.

16

Results of Operations

Three months ended June 30, 2013 versus three months ended June 30, 2012:

In thousands of U.S. Dollars	Three Months Ended June 30, 2013			Three Months Ended June 30, 2012			Change
Revenue	$	-		$	-		$	-
Operating expenses:
Research and development		554			860			(306	)
General and administration		373			390			(17	)
Total operating expenses		927			1,250			(323	)
Loss from operations		927			1,250			323
Unrealized gain/(loss) on derivatives		7,535			645			6,890
Interest and other (loss) / income		(1	)		3			(4	)
Net  gain/(loss) and total comprehensive gain/(loss)	$	6,607		$	(602	)	$	7,209

There was a significant decrease in research and development expenses for the three months ended June 30, 2013 as compared to the same period in 2012 due to the winding down of the Phase II eniluracil trial. Research and development costs are impacted by the clinical support costs associated with the amount of patients enrolled and participating in the trial during the financial period.

The Company recorded an unrealized gain on derivatives of $7,535 in the three months ended June 30, 2013 compared to an unrealized gain of $645 in the three months ended June 30, 2012. These derivatives have been recorded at their fair value as a liability at issuance and will continue to be re-measured at fair value as a liability at each subsequent balance sheet date. Any change in value between reporting periods will be recorded as unrealized gain/(loss). These warrants will continue to be reported as a liability until such time as they are exercised or expire. The fair value of these warrants is estimated using the Black-Scholes option-pricing model.

Our results of operations for the six months ended June 30, 2013 versus six months ended June 30, 2012 were as follows:

In thousands of U.S. Dollars	Six Months Ended June 30, 2013		Six Months Ended June 30, 2012		Change
Revenue	$	-	$	-	$	-
Operating expenses:
Research and development		732		1,157		(425	)
General and administration		732		710		22
Total operating expenses		1,464		1,867		(403	)
Unrealized/realized gain/(loss) on derivatives		3,962		3,971		(9	)
Interest and other income (loss)		1		8		(7	)
Net income	$	2,499	$	2,112	$	387

Total operating expenses were approximately $1,464 for the six months ended June 30, 2013 and approximately $1,867 for the six months ended June 30, 2012. The decrease of $403 was primarily due to decreased costs associated with the Company’s Phase II eniluracil trial offset by a slight increase in general and administrative expenses. Research and development expenses decreased approximately $425 in the period ended June 30, 2013 compared to the similar period as a result of the study concluding enrollment in December 2012.

17

Quarterly Information

The following table presents selected consolidated financial data for each of the last eight quarters through June 30, 2013, as prepared under U.S. GAAP (U.S. dollars in thousands, except per share information):

Period	Net Income (Loss) for the Period			Basic and Diluted Net Income(Loss) per Common Share
September 30, 2011	$	(3,144	)	$	(0.17	)
December 31, 2011		3,508			0.14
March 31, 2012		2,715			0.11
June 30, 2012		(602	)		(0.02	)
September 30, 2012		(764	)		(0.03	)
December 31, 2012		(6,511	)		(0.26	)
March 31, 2013		(4,108	)		(0.16	)
June 30, 2013		6,607			0.26

Liquidity and Capital Resources

In thousands of U.S. dollars	June 30, 2013			December 31, 2012
Selected Asset and Liability Data:
Cash and cash equivalents	$	1,007		$	2,303
Other current assets		23			62
Derivative  liabilities		2,678			6,640
Other current liabilities		781			682
Long term liabilities
Working capital [Current Assets - Current Liabilities excluding the derivative liabilities]		249			1,683
Selected Stockholders’ Equity Data:
Common stock	$	65,952		$	65,952
Deficit accumulated during the development stage		(108,045	)		(110,543	)
Total stockholders’ equity (deficiency)		2,429			(4,957	)

Cash and cash equivalents were $2,303 at December 31, 2012 and $1,007 at June 30, 2013. The decrease of approximately $1,296 is attributable to the Company's operating expenses.

Since our inception on September 3, 1996, we have financed our operations through the sale of equity and debt securities and have raised gross proceeds totaling approximately $89.5 million through June 30, 2013.We have incurred net losses and negative cash flow from operations each year, and we had an accumulated deficit of approximately $108,045 at June 30, 2013. We have not generated any revenues to date through the sale of products. We do not expect to have significant revenues or income, other than interest income, until we are able to sell our product candidates after obtaining applicable regulatory approvals or we establish collaborations that provide us with up-front payments, licensing fees, milestone payments, royalties or other payments.

Net cash used in operating activities for the six months ended June 30, 2013 was $1,296, as compared to $1,711 during the same period in 2012. This decrease is due to decreased research and development expenses incurred from the Phase II eniluracil trial. There was no net cash provided by financing activities for the six months ended June 30, 2013 similar to the comparable period in 2012.

18

Outstanding Share Information

The outstanding share data for our company as of June 30, 2013 (in thousands):

	June 30, 2013
Common shares		25,158
Warrants		18,035
Stock options		5,533
Total		48,726

Financial Instruments

We invest excesscash and cash equivalents in high credit quality investments held by financial institutions in accordance with our investment policy designed to protect the principal investment. At June 30, 2013, we had approximately $0.9 million in cash accounts. We have not experienced any loss or write down of our money market investments for the six months ended June 30, 2013 and 2012, respectively.

Our investment policy is to manage investments to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment. Investments may be made in U.S. or Canadian obligations and bank securities, commercial paper of U.S. or Canadian industrial companies, utilities, financial institutions and consumer loan companies, and securities of foreign banks provided the obligations are guaranteed or carry ratings appropriate to the policy. Securities must have a minimum Dun & Bradstreet rating of A for bonds or R1 low for commercial paper. The policy also provides for investment limits on concentrations of securities by issuer and maximum-weighted average time to maturity of twelve months. This policy applies to all of our financial resources.

The policy risks are primarily the opportunity cost of the conservative nature of the allowable investments. As our main purpose is research and development, we have chosen to avoid investments of a trading or speculative nature.

Off-Balance Sheet Arrangements

Since our inception, we have not had any material off-balance sheet arrangements. In addition, we do not engage in trading activities involving non-exchange traded contracts. As such, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such activities.

Contractual Obligations and Commitments

The Company had no material commitments as of June 30, 2013. Under the service agreement with OCT Group LLC entered in August 2010, the Company was required to make several payments over the course of our Phase II clinical trial in Russia. The payments were made upon the fulfillment of several milestones during the clinical trial including regulatory approval of trial, enrollment of patients and the completion of therapy of patients. The Company amended the agreement in April 2011 and August 2011 for the addition of additional sites for OCT to service during the Phase II clinical trial. The Company amended the agreement in June 2012 for the transition to a paper-based database to be developed by OCT. In addition, the Company amended the agreement on October 29, 2012 for the addition of up to 20 patients to be enrolled. The service agreement with OCT expired on June 30, 2013.

Under the license agreement with Oregon Health & Science University (OHSU) for STS dated February 20, 2013, upon the first commercial sale of STS we may become responsible for a payment to OHSU of up to $0.1 million. Prior to this new license agreement with OHSU, the previous license agreement with OHSU dated September 26, 2002, included that the Company may have become responsible for a payment to OHSU of up to $0.5 million upon the successful completion of the Phase III clinical trial with COG or SIOPEL. The license agreement with OHSU dated September 26, 2002 was terminated on February 20, 2013. Royalty payments are contingent on sales.

In the event of his termination with us other than for cause, the Company will pay Rostislav Raykov $140 in severance. In the event of his termination with us other than for cause, the Company will pay Robert Andrade $140 in severance.

19

Research and Development

Our research and development efforts have been focused on the development of cancer therapeutics and currently include eniluracil and STS.

We have established relationships with contract research organizations, universities and other institutions, which we utilize to perform many of the day-to-day activities associated with our drug development. Where possible, we have sought to include leading scientific investigators and advisors to enhance our internal capabilities.

Research and development expenses for the three months ended June 30, 2013 and 2012 were $554 and $860 respectively and for the six months then ended totaled $732 and $1,157, respectively. The decrease in research and development expenses relates to the conclusion of enrollment of the Phase II eniluracil trial in December 2012. As a result of the wind down of the trial, research and development expenses including patient monitoring, database support and drug shipment costs to Russia significantly decreased.

Our product candidates are in various stages of development and still require significant, time-consuming and costly research and development, testing and regulatory clearances. In developing our product candidates, we are subject to risks of failure that are inherent in the development of products based on innovative technologies. For example, it is possible that any or all of these products will be ineffective or toxic, or will otherwise fail to receive the necessary regulatory clearances. There is a risk that our product candidates will be uneconomical to manufacture or market or will not achieve market acceptance. There is also a risk that third parties may hold proprietary rights that preclude us from marketing our product candidates or that others will market a superior or equivalent product. As a result of these factors, we are unable to accurately estimate the nature, timing and future costs necessary to complete the development of these product candidates. In addition, we are unable to reasonably estimate the period when material net cash inflows could commence from the sale, licensing or commercialization of such product candidates, if ever.

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expense during the reporting period. These estimates are based on assumptions and judgments that may be affected by commercial, economic and other factors. Actual results could differ from these estimates.

Our accounting policies are consistent with those presented in our annual consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2012.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Money Market Investments

We maintain an investment portfolio consisting of U.S. or Canadian obligations and bank securities and money market investments in compliance with our investment policy. We do not hold any mortgaged-backed investments in our investment portfolio. Securities must have a minimum Dun & Bradstreet rating of A for bonds or R1 low for commercial paper. The policy also provides for investment limits on concentrations of securities by issuer and maximum-weighted average time to maturity of twelve months. This policy applies to all of our financial resources.

At June 30, 2013, we had approximately $913 in money market investments which typically have minimal market risk. The financial markets have been volatile resulting in concerns regarding the recoverability of money market investments. We have not experienced any loss or write down of our money market investments.

Our investment policy is to manage investments to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment. Our risk associated with fluctuating interest rates on our investments is minimal and not significant to the results of operations. We currently do not use interest rate derivative instruments to manage exposure to interest rate changes. As the main purpose is research and development, we have chosen to avoid investments of a trade or speculative nature.

Foreign Currency Exposure

We are subject to foreign currency risks as we conduct certain clinical development activities in Canada, the United Kingdom, Europe, Russia and the Pacific Rim. To date, we have not employed the use of derivative instruments to hedge our exposure to changes in currency exchange rates; however, we do hold Canadian dollars which we use to pay certain research and other corporate obligations conducted in Canada. At June 30, 2013 we held approximately $0.01 million Canadian dollars.

20

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures.

In connection with the preparation of this report, anevaluation was carried out by the Company’s management, with the participation of the Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (“Exchange Act”)) as of June 30, 2013. Disclosure controls and procedures are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms and that such information is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Based on that evaluation, the Company’s management concluded, as of the end of the period covered by this report, that the Company’s disclosure controls and procedures were not effective as a result of having identified one material weakness in our internal control over financial reporting, as described in further detail below.

Our management has identified a control deficiency because we lack sufficient staff to segregate accounting duties. We believe the control deficiency results primarily because we have one full time employee performing all accounting and financial reporting duties. As a result, we do not maintain adequate segregation of duties within our critical financial reporting applications, the related modules and financial reporting processes. This control deficiency could result in a misstatement of balance sheet and income statement accounts in our interim or annual consolidated financial statements that would not be detected. Accordingly, management has determined that this control deficiency constitutes a material weakness.

After the Company filed its Current Report on Form 8-K under Item 4.02 on November 2, 2010, the Company took remedial actions for our previously reported internal control weakness of not maintaining sufficient personnel with an appropriate level of technical accounting knowledge, experience, and training in the application of U.S. GAAP commensurate with our complexity and our financial accounting and reporting requirements. In 2012, the Company has contracted additional personnel with experience in the application of U.S. GAAP financial accounting and reporting requirements in order to assist management in its financial accounting and reporting functions. As a result, the Company believes that this added experience and knowledge has remediated the previously disclosed material internal control weakness described above.

Further, the Company believes that this has helped remedy, but has not eliminated, the control deficiency described above regarding lack of sufficient staff to segregate accounting duties. To finance our continuing operations, we will need to raise additional funds beyond those from our April 2010 private placement and the Rights Offering and, as disclosed elsewhere in this report, there remains substantial uncertainty of our ability to continue as a going concern and the failure to obtain such funds might require us to further delay, scale back or eliminate certain research and development studies, consider business combinations, or even shut down some, or all, of our operations. Once we are able to secure such additional financing, we anticipate hiring additional personnel with appropriate technical accounting knowledge, experience, and training in the application of U.S. GAAP to supplement our current accounting staff.

(b) Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) identified in connection with the evaluation of our internal control over financial reporting that occurred during the fiscal quarter ended June 30, 2013 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

21

PART II: OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors.

Additional Risks Related to our Business

We do not presently have the financial or human resources to complete Phase III trials for our lead product candidates.

We do not presently have the financial or human resources internally to complete Phase III trials for any of our lead product candidates.   If these trials are successful, and if we decide to continue to develop eniluracil, we will need additional funding, or we will need to enlist a partner to conduct future trials.

We are currently developing STS in Phase III trials in collaboration with the International Childhood Liver Tumour Strategy Group, known as SIOPEL and the Children's Oncology Group.  It is possible SIOPEL and the Children's Oncology Group may not conduct or complete the clinical trials with STS as currently planned.  Such collaborators might not commit sufficient resources to the development of our product candidates, which may lead to significant delays.  We have already experienced significant delays in the activation of the Children's Oncology Group trial and subsequent accrual of patients into the Children's Oncology Group and SIOPEL clinical trials.  We may not be able to independently develop or conduct such trials ourselves.  

We continue to seek a licensing or funding partner for the further development of one or all of our product candidates.  If a partner for one or all of these technologies is not found, we may not be able to further advance these products.  If a partner is found, the financial terms that they propose may not be acceptable to us.

There is no assurance that we will successfully develop a commercially viable product. 

Since our formation in September 1996, we have engaged in research and development programs.  We have generated no revenue from product sales, we do not have any products currently available for sale, and none are expected to be commercially available for sale until we have completed additional clinical trials, if at all.  There can be no assurance that the research we fund and manage will lead to commercially viable products. Our intention is to commence a Phase II study for eniluracil and STS is currently in a Phase III study. Our products must still undergo substantial additional regulatory review prior to commercialization.

We anticipate the need for additional capital in the future and if we cannot raise additional capital, we will not be able to fulfill our business plan.

We need to obtain additional funding in the future in order to finance our business strategy, operations and growth. We may not be able to obtain additional financing in sufficient amounts or on acceptable terms when needed. If we fail to arrange for sufficient capital on a timely basis, we may be required to curtail our business activities until we can obtain adequate financing. Debt financing must be repaid regardless of whether or not we generate profits or cash flows from our business activities. Equity financing may result in dilution to existing stockholders and may involve securities that have rights, preferences, or privileges that are senior to our common stock or other securities. If we cannot raise sufficient capital when necessary, we will likely have to curtail operations and you may lose part or all of your investment.

We may be unable to effectively deploy the proceeds from our financings for the development of Eniluracil.

In April 2010, we announced the closing of a private placement for proceeds of CAD $7.2 million and in March 2011, we announced the closing of a Rights Offering for proceeds of approximately$2.5 million.  Any inability on our part to manage effectively the deployment of this capital could limit our ability to successfully develop Eniluracil.

22

Additional Risks Related to our Common Stock

We may be unable to maintain the listing of our common stock on the TSX and that would make it more difficult for stockholders to dispose of their common stock.

Our common stock is currently listed on the TSX. The TSX has rules for continued listing, including minimum market capitalization and other requirements, that we might not meet in the future, particularly if the price of our common stock does not increase or we are unable to raise additional capital to continue operations. In January 2009, our common stock was delisted from the AMEX as we did not meet the continued listing requirements of that exchange. On September 8, 2012, the Toronto Stock Exchange issued an official delisting review of our common stock. The remedial delisting review was initiated because the value of the shares of our common stock that are held by “public shareholders” had been below the CAD $2.0 million threshold required under the TSX continuing listing standards for a period of 30 consecutive trading days. On January 7, 2013, the Toronto Stock Exchange completed its review of the Company and determined that the Company met TSX's continued listing requirements.

Delisting from the TSX would make it more difficult for stockholders to dispose of their common stock and more difficult to obtain accurate quotations on our common stock. This could have an adverse effect on the price of our common stock. There can be no assurances that a market maker will make a market in our common stock on the OTCQB or any other stock quotation system after delisting. Furthermore, securities quoted on the Pink Sheets generally have significantly less liquidity than securities traded on a national securities exchange, not only in the number of shares that can be bought and sold, but also through delays in the timing of transactions and lower market prices than might otherwise be obtained. As a result, stockholders might find it difficult to resell shares at prices quoted in the market or at all. Furthermore, because of the limited market and generally low volume of trading in our common stock, our common stock is more likely to be affected by broad market fluctuations, general market conditions, fluctuations in our operating results, changes in the market’s perception of our business, and announcements made by us, our competitors or parties with whom we have business relationships. Our ability to issue additional securities for financing or other purposes, or to otherwise arrange for any financing we may need in the future, may also be materially and adversely affected by the fact that our securities are not traded on a national securities exchange.

Our common stock is deemed to be a “penny stock,” which may make it more difficult for investors to sell their shares due to suitability requirements.

Our common stock is subject to Rule 15g-1 through 15g-9 under the Exchange Act, which imposes certain sales practice requirements on broker-dealers which sell our common stock to persons other than established customers and “accredited investors” who are generally individuals with a net worth in excess of $1,000,000 (excluding the value of their primary residence) or annual incomes exceeding $200,000 or $300,000 together with their spouses. For transactions covered by this rule, a broker-dealer must make a special suitability determination for the purchaser and have received the purchaser’s written consent to the transaction prior to the sale. This rule adversely affects the ability of broker-dealers to sell our common stock and the ability of our stockholders to sell their shares of common stock.

Additionally, our common stock is subject to the SEC regulations for “penny stock.” Penny stock includes any equity security that is not listed on a national exchange and has a market price of less than $5.00 per share, subject to certain exceptions. The regulations require that prior to any non-exempt buy/sell transaction in a penny stock, a disclosure schedule set forth by the SEC relating to the penny stock market must be delivered to the purchaser of such penny stock. This disclosure must include the amount of commissions payable to both the broker-dealer and the registered representative and current price quotations for the common stock. The regulations also require that monthly statements be sent to holders of penny stock that disclose recent price information for the penny stock and information on the limited market for penny stocks. These requirements adversely affect the market liquidity of our common stock.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On April 3, 2013 and May 14, 2013, the Company issued 25,000 and 10,204 stock options, respectively, to certain consultants and officers of the Company. The options were issued in a private placement exempt under Section 4(2) of the Securities Act of 1933, as amended (the "Securities Act"). The options were issued in USD dollar denominated grants at an exercise price of $0.80 and $0.98 per share, respectively, and are exercisable for a period of 7 years from the grant date.

Item 3. Default Upon Senior Securities

None.

23

Item 4. Mine Safety Disclosure

N/A

Item 5. Other Information

None

Item 6. Exhibits

Exhibit
No. Description

31.1 Certification of Chief Executive Officer of the Company in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

31.2 Certification of Chief Financial Officer of the Company in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

32.1 Certification of Chief Executive Officer and Chief Financial Officer of the Company in accordance with Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).

99.1 Press Release for Quarter Ended June 30, 2013 (filed herewith).

101.1 Interactive Data File

24

SIGNATURES

Pursuant to requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Adherex Technologies Inc.
Date: August 9, 2013	By:	/s/ Rostislav Raykov
		Rostislav Raykov
		Chief Executive Officer
		(principal executive officer)
Date: August 9, 2013	By:	/s/ Robert Andrade
		Robert Andrade
		Chief Financial Officer
		(principal financial and chief accounting officer)

25

EX-31.1

Exhibit 31.1

ADHEREX TECHNOLOGIES INC

CERTIFICATION

I, Rostislav Raykov, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the period ended June 30, 2013of Adherex Technologies Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures,or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2013

By:	/s/Rostivlav Raykov
	Rostislav Raykov
	Chief Executive Officer

EX-31.2

Exhibit 31.2

ADHEREX TECHNOLOGIES INC.

CERTIFICATION

I, Robert Andrade, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the period ended June 30, 2013 of Adherex Technologies Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2013

By:	/s/ Robert Andrade
	Robert Andrade
	Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Adherex Technologies Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2013 (the “Report”), each of the undersigned, Rostislav Raykov, Chief Executive Officer of the Company, and Robert Andrade, Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2013

By:	/s/ Rostislav Raykov
	Rostislav Raykov
	Chief Executive Officer

Date: August 9, 2013

By:	/s/ Robert Andrade
	Robert Andrade
	Chief Financial Officer

EX-99.1

ADHEREX REPORTS RECENT DEVELOPMENTS AND SECOND QUARTER JUNE 30, 2013 FINANCIAL RESULTS

· Data from Phase III Sodium Thiosulfate (STS) Trial Expected in Q3 2013

· If convincing efficacy and safety results are received from the STS Phase III trial, Adherex plans to propose to the FDA the filing of a New Drug Application

· Company to Focus on Development of STS for Prevention of Hearing Loss in Pediatric Oncology Patients

· Possibility of Commercial Partnership for Eniluracil (EU) will be explored

Research Triangle Park, NC, August 9, 2013 - - Adherex Technologies Inc. (TSX:AHX, OTCQB: ADHXF), today reported its financial results and recent developments for the second quarter ended June 30, 2013. All amounts are in U.S. dollars unless otherwise specified.

Corporate Developments

Adherex will focus its remaining resources on the development of Sodium Thiosulfate (STS), a chemoprotectant for the prevention of hearing loss in pediatric oncology patients undergoing platinum-based chemotherapy. The Company plans to seek a partnership for eniluracil (EU) and at this time will not undertake additional clinical work.

“We think that STS has the potential to fill an important unmet medical need in pediatric oncology” stated Mr. Rosty Raykov, Chief Executive Officer of Adherex, “Platinum based drugs are broadly used in children undergoing chemotherapy where they are known to produce profound and irreversible hearing loss. Currently, there is no effective means to prevent this debilitating side effect. Because the two Phase III clinical trials with STS are conducted and supported by cooperative oncology groups, we expect to advance this product to market with modest additional expenditure.”

"We encourage our shareholders to visit our website and review our updated corporate presentation, which has additional details on our plans for STS," added Mr. Raykov.

Sodium Thiosulfate (STS)

STS is a chemoprotectant being developed by Adherex to reduce or prevent hearing loss in oncology patients resulting from treatment with platinum-based chemotherapy drugs. The initial focus is on the pediatric market.  Hearing loss following cisplatin exposure affects approximately 2,000 children in the US every year. STS has received Orphan Drug Designation in the United States for the prevention of platinum-induced ototoxicity in pediatric patients.  In addition, Adherex has licensed intellectual property rights for the use of STS as a chemoprotectant from Oregon Health & Science University.

STS is a water- soluble thiol compound and acts as a chemical reducing agent.  It is FDA approved for the treatment of cyanide poisoning and has been used in oncology to prevent cisplatin nephrotoxicity. It is thought that hearing loss caused by platinum compounds result from the deposition of protein-bound platinum in the cochlea and STS binds platinum/protein complexes thereby potentially minimizing their toxicity. At a bolus dose of 20 g/m² over 15 minutes, STS has sufficient high plasma concentrations to rapidly, covalently bind to any residual extracellular cisplatin and thereby possibly prevent ototoxicity.  Because STS is to be administered six hours after cisplatin, antitumor efficacy of cisplatin should not be compromised.

STS is being investigated by cooperative groups in two Phase III clinical studies to evaluate the reduction of ototoxicity and impact on survival:

Study ACCL0431: “A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children”, conducted by the Children’s Oncology Group (COG), finished enrollment of 135 patients in 1Q 2012.  These patients had been previously diagnosed with one of five rare childhood cancers typically treated with intensive cisplatin therapy, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, and medulloblastoma. Final data from the study is expected to be released by COG in the third quarter of 2013. 

SIOPEL 6: “A Multicenter Open Label Randomized Phase III Trial of the Efficacy of Sodium Thiosulphate in Reducing Ototoxicity in Patients Receiving Cisplatin Chemotherapy for Standard Risk Hepatoblastoma” is being conducted by The International Childhood Liver Tumour Strategy Group, SIOPEL. As of this date, the study has enrolled 76 out of a planned 102 patients. SIOPEL 6 is being conducted in standard risk hepatoblastoma patients where the effectiveness of the platinum treatment is known to be very high. The first two interim safety analyses were conducted after 20 and 52 patients, and in each case, the Independent Data Monitoring Committee recommended continuation of the study. An interim efficacy analysis is planned with the possibility for early completion of the trial, if there is greater than expected difference in hearing loss between the two treatment arms.

STS Development Plan

Adherex presented to FDA’s Pediatric Oncology Drug Advisory Committee (ODAC) on November 1, 2011. The Committee acknowledged the challenge of demonstrating that STS does not reduce the efficacy of cisplatin and agreed an adult study would not be appropriate. The presentation and minutes from the meeting are available to download from the FDA and Adherex websites. If convincing efficacy and safety results are received from COG ACCL0431, Adherex plans to propose to the FDA the filing of a New Drug Application (NDA) based on this single study.

Eniluracil Update

As previously disclosed, on May 22, 2013, the FDA made a recommendation as to the clinical trial that would be required to support registration of eniluracil in Metastatic Breast Cancer. After review of the FDA’s recommendation, the Company determined that the recommended trial would be larger than that originally envisioned and proposed by the Company. Adherex management believes it would be in the best interests of shareholders and the cancer community to focus on seeking a partnership for eniluracil, which may include the Company evaluating viable indications for eniluracil other than MBC. Data from the Phase 2 trial will be submitted for publication in a scientific journal.

Financial Update

“Adherex has taken proactive steps to eliminate most of its payables and reduce its cash burn to a minimum. The Company does not anticipate the need for immediate funding, until results from COG are reported later in the year, " said Mr. Raykov.

The Company reported a net loss from operations of $0.9 million excluding the $7.5 million non-cash gain on derivatives for the second quarter ended June 30, 2013, compared to a net loss from operations of $1.2 million excluding the non-cash gain of $0.6 million in the same period in 2012. The decrease in the net loss from operations excluding the non-cash impact of derivatives is primarily due to an decrease in research and development expenses associated with the Company Phase II eniluracil trial.

Research and development expenses totaled $0.5 million for the second quarter ended June 30, 2013, as compared to $0.9 million in the same period in 2012. The decrease in research and development expenses relates to the conclusion of enrollment and ongoing clinical support of the Phase II eniluracil trial.

The Company reported a net loss from operations of $1.5 million excluding the $4.0 million non-cash gain on derivatives for the six month period ended June 30, 2013, compared to a net loss from operations of $1.9 million excluding the non-cash gain of $4.0 million in the same period in 2012. The decrease in the net loss from operations excluding the non-cash impact of derivatives is primarily due to a decrease in research and development expenses associated with the Company Phase II eniluracil trial offset by a slight increase in general and administrative expenses.

Research and development expenses totaled $0.7 million for the six month period ended June 30, 2013, as compared to $1.2 million in the same period in 2012. The decrease in research and development expenses relates to the wind down of the Phase II eniluracil trial which completed enrollment in December 2012.

Cash and cash equivalents totaled $1.0 million at June 30, 2013, compared to $2.3 million at December 31, 2012. At June 30, 2013, the Company had working capital totaling approximately $0.25 million. The decreased cash balance is the result of the Company’s operating expenses relating to the Phase II eniluracil study. On August 1, 2013, Adherex settled a balance of $0.5 million in accounts payable for $0.23 million, the result would have made the Company's working capital at June 30, 2013 to be $0.5 million. The selected financial data presented below is derived from our unaudited consolidated financial statements which were prepared in accordance with U.S. generally accepted accounting principles. The complete interim consolidated financial statements for the period ended June 30, 2013 and management's discussion and analysis of financial condition and results of operations will be available via www.sec.gov and www.sedar.com.

Adherex Technologies Inc.

Selected Financial Data

(U.S. dollars in thousands except per share amounts)

Interim Unaudited Consolidated Balance Sheets:	June 30, 2013			December 31, 2012
Assets:
Cash and cash equivalents	$	1,007		$	2,303
Other current assets		23			62
Total assets	$	1,030		$	2,365
Liabilities and stockholders’ equity:
Current liabilities	$	798		$	682
Derivative liabilities		2,678			6,640
Other long-term liabilities		-			-
Total stockholders’ equity		(2,429	)		(4,957	)
Total liabilities and stockholders’ equity (deficiency)	$	1,030		$	2,365

Interim Unaudited Consolidated Statements of Operations:	Three Months Ended						Six Months Ended
	June 30, 2013			June 30, 2012			June 30, 2013			June 30, 2012
Revenue	$	-		$	-		$	-		$	-
Operating expenses:
Research and development		554			860			732			1,157
General and administrative		373			390			732			710
Loss from operations		(927	)		(1,250	)		(1,464	)		(1,867	)
Unrealized gain (loss)		7,535			645			3,962			3,971
Interest income and other		(1	)		3			1			8
Net income/(loss) and comprehensive income/(loss)	$	6,607		$	(602	)	$	2,499		$	2,112
Basic and diluted net loss per common share	$	0.26		$	(0.02	)	$	0.10		$	0.08

Except for historical information described in this press release, all other statements are forward-looking. Forward-looking statements are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, and its ability to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2012. Adherex Technologies, Inc. disclaims any obligation to update these forward-looking statements except as required by law.

For a more detailed discussion of related risk factors, please refer to our public filings available at www.sec.gov and www.sedar.com.

For further information, please contact:

Rosty Raykov
Chief Executive Officer
Adherex Technologies Inc.
T: (919) 636-5144

XML

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2013

Fair Value Disclosures [Abstract]

Assets/Liabilities Measured at Fair Value on Recurring Basis

Assets/Liabilities Measured at Fair Value on a Recurring Basis

	Fair Value Measurement at June 30, 2013
	Quoted Price in Active Markets		Significant Other		Significant
	for Identical Instruments		Observable Inputs		Unobservable Inputs
	Level 1		Level 2		Level 3		Total
Assets
Cash & Cash equivalents		94	$	913		-	$	1,007
Liabilities
Derivative liabilities		-		2,678		-		2,678
TOTAL		94	$	3,591		-	$	3,685

XML

Consolidated Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended		202 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
Revenue	$ 0	$ 0	$ 0	$ 0	$ 0
Operating expenses:
Research and development	554	860	732	1,157	69,900
Impairment of capital assets	0	0	0	0	386
Gain on deferred lease inducements	0	0	0	0	(497)
Acquired in-process research and development	0	0	0	0	13,094
General and administrative	373	390	732	710	32,826
Total operating expenses	927	1,250	1,464	1,867	115,709
Loss from operations	(927)	(1,250)	(1,464)	(1,867)	(115,709)
Other income (expense):
Settlement of Cadherin litigation	0	0	0	0	(1,283)
Interest expense	0	0	0	0	(19)
Unrealized/realized gain on derivatives	7,535	645	3,962	3,971	7,219
Other income	2	0	2	0	261
Interest (loss)/income and other	(3)	3	(1)	8	2,896
Total other income (expense), net	7,534	648	3,963	3,979	9,074
Net income/(loss) and total comprehensive income / (loss)	$ 6,607	$ (602)	$ 2,499	$ 2,112	$ (106,635)
Basic and diluted net income /(loss) per common share	$ 0.26	$ (0.02)	$ 0.10	$ 0.08
Weighted-average number of common shares outstanding, basic	25,158	25,158	25,158	25,158
Weighted-average common shares outstanding, diluted	25,639	25,158	25,714	25,158

XML

Stockholders' Equity

6 Months Ended

Jun. 30, 2013

Stockholders' Equity [Abstract]

Stockholders' Equity

4. Stockholders' Equity

Warrants to purchase common stock

At June 30, 2013, the Company had the following warrants outstanding to purchase common stock priced in Canadian dollars with a weighted average exercise price of CAD $1.44 and a weighted average remaining life of 2.0 years:

Warrant Description	Common Shares Issuable Upon Exercise of Outstanding Warrants at June 30, 2013		Exercise Price In CAD Dollars		Expiration Date
Investor warrants (1)		13,337	$	1.44	April 30, 2015
Investor warrants (2)		4,698	$	1.44	March 29, 2016
		18,035

(1) On April 30, 2010, the Company announced that it had completed a first closing of a non-brokered private placement (“Private Placement”) of 240,066 units, at a price of CAD $0.03 per unit for net proceeds of CAD $7,200. Each unit consisted of one common share and one common share purchase warrant (a “Warrant”). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD $1.44 per whole share for a period of five years from the issue date.

(2) On March 29, 2011, the Company announced that it had completed a non-brokered rights offering of 84,559 units, at a price of CAD $0.03 per unit for total net proceeds of $2,547. Each unit consisted of one common share and one common share purchase warrant (a “Warrant”). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD $1.44 per whole share for a period of five years from the issue date.

Stock option plan

The Compensation Committee of the Board of Directors administers the Company’s stock option plan.  The Compensation Committee designates eligible participants to be included under the plan and approves the number of options to be granted from time to time under the plan. On June 24, 2010, at the Company’s annual meeting, shareholders approved an amendment to the Company’s Stock Option Plan (the “Plan Maximum Amendment”). The Plan Maximum Amendment relates to changing the maximum number of shares of common stock issuable under the Stock Option Plan from a fixed number of 20,000 to the number of shares that represent twenty five percent (25%) of the total number of all issued and outstanding shares of common stock from time to time.  On June 18, 2013, at the Company’s annual meeting, shareholders approved the continuation of the Plan Maximum Amendment for three more years until June 28, 2016. Based upon the current shares outstanding, a maximum of 6,290 options are authorized for issuance under the plan.  The option exercise price for all options issued under the plan is based on the fair value of the underlying shares on the date of grant.  All options vest within three years or less and are exercisable for a period of seven years from the date of grant.  The stock option plan, as amended, allows the issuance of Canadian and U.S. dollar grants.  During the three and six-month periods ended June 30, 2013 the Company recognized total stock-based compensation expense of $29 and $29. During the three and six-month periods ended June 30, 2012 the Company recognized total stock-based compensation expense of $52 and $52.

Valuation assumptions

The value of options granted in the three months ended June 30, 2013 and June 30, 2012, respectively were estimated using the Black-Scholes option-pricing model, using the following assumptions: expected dividend 0% and 0%, respectively; risk-free interest rate of 1.2-1.32% and 1.125 – 1.25%, respectively; expected volatility of 159-163% and 132-3%, respectively; and a 7 year expected life.

Stock option activity

The following is a summary of option activity for the six months ended June 30, 2013 for stock options denominated in Canadian dollars:

Options in thousands	Number of Options (thousands)		Weighted-average Exercise Price
Outstanding at December 31, 2012		4,171		CAD $ 0.78
Granted		-		-
Exercised		-		-
Expired		-		-
Outstanding at June 30, 2013		4,171		CAD $ 0.78

Canadian dollar denominated options issued to contractors vest immediately and are treated as derivative liabilities. They are recorded at fair value estimated using the Black Scholes model with the gain or loss reported as unrealized gain(loss).

The following is a summary of option activity for the six months ended June 30, 2013 for stock options denominated in U.S. dollars:

Options in thousands	Number of Options (thousands)		Weighted-average Exercise Price
Outstanding at December 31, 2012		1,327	$	0.67
Granted		35		0.86
Exercised		-		-
Expired		-		-
Outstanding at June 30, 2013		1,362	$	0.67

XML

Shareholders' Equity (Warrants Outstanding to Purchase Common Stock) (Parenthetical) (Details)		1 Months Ended		1 Months Ended
	Jun. 30, 2013	Apr. 30, 2010 Private Placement [Member] CAD	Jun. 30, 2013 Private Placement [Member]	Mar. 29, 2011 Non-Broker Rights Offering [Member] USD ($)	Mar. 29, 2011 Non-Broker Rights Offering [Member] CAD	Apr. 30, 2010 Non-Broker Rights Offering [Member]	Jun. 30, 2013 Non-Broker Rights Offering [Member]	Jun. 30, 2003 Non-Broker Rights Offering [Member]
Class of Warrant or Right [Line Items]
Issuance of stock		240,066		84,559	84,559
Issuance of stock, price per share		0.03			0.03
Proceeds from issuance of unit		7,200		$ 2,547
Common shares issuable upon exercise of outstanding warrants	18,035		18					18
Warrants, exercise Price			1.44				1.44
Warrants, term		5 years				5 years

XML

Going Concern - Additional Information (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended			6 Months Ended			10 Months Ended	12 Months Ended															202 Months Ended
	Jun. 30, 2013	Mar. 31, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2004	Jun. 30, 1997	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007	Dec. 31, 2006	Dec. 31, 2005	Jun. 30, 2004	Jun. 30, 2003	Jun. 30, 2002	Jun. 30, 2001	Jun. 30, 2000	Jun. 30, 1999	Jun. 30, 1998	Jun. 30, 2013
Going Concern [Line Items]
Net Income Loss	$ 6,607	$ (4,108)	$ (602)	$ 2,499	$ 2,112	$ (6,594)	$ (37)	$ (5,163)	$ 4,685	$ (7,824)	$ (3,012)	$ (13,600)	$ (13,357)	$ (16,440)	$ (13,871)	$ (6,872)	$ (17,795)	$ (3,732)	$ (2,524)	$ (1,605)	$ (958)	$ (398)	$ (106,635)
Unrealized Gain (Loss) on Derivatives	7,535		645	3,962	3,971																		7,219
Net Cash Used In Operating Activities	(889)		(1,133)	(1,296)	(1,711)																		(86,333)
Development Stage Enterprise Deficit Accumulated During Development Stage	$ 108,044			$ 108,044				$ 110,543															$ 108,044

XML

Fair Value Measurements - Additional Information (Details)	6 Months Ended
	Jun. 30, 2013
Warrant [Member]
Assumptions used to Determine Fair Value Options [Line Items]
Expected dividend rate	0.00%
Warrant [Member] | Minimum [Member]
Assumptions used to Determine Fair Value Options [Line Items]
Risk free interest rate	1.21%
Expected volatility rate	148.00%
Expected life	1 year 9 months 29 days
Warrant [Member] | Maximum [Member]
Assumptions used to Determine Fair Value Options [Line Items]
Risk free interest rate	1.35%
Expected volatility rate	155.00%
Expected life	2 years 9 months
Employee Stock Option [Member]
Assumptions used to Determine Fair Value Options [Line Items]
Expected dividend rate	0.00%
Employee Stock Option [Member] | Minimum [Member]
Assumptions used to Determine Fair Value Options [Line Items]
Risk free interest rate	1.66%
Expected volatility rate	150.00%
Expected life	4 years 4 months 24 days
Employee Stock Option [Member] | Maximum [Member]
Assumptions used to Determine Fair Value Options [Line Items]
Risk free interest rate	1.78%
Expected volatility rate	152.00%
Expected life	4 years 10 months 24 days

XML

Fair Value Measurements (Assets/Liabilities Measured at Fair Value on Recurring Basis) (Details) (USD $)	Jun. 30, 2013
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Cash and cash equivalents	$ 1,007
Derivative liabilities	2,678
TOTAL	3,685
Quoted Price in Active Markets for Identical Instruments Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Cash and cash equivalents	94
Derivative liabilities	0
TOTAL	94
Significant Other Observable Inputs Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Cash and cash equivalents	913
Derivative liabilities	2,678
TOTAL	3,591
Significant Unobservable Inputs Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Cash and cash equivalents	0
Derivative liabilities	0
TOTAL	$ 0

XML

Shareholders' Equity - Additional Information (Details) (USD $) Share data in Thousands, unless otherwise specified	1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 24, 2010	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Stockholders Equity Note [Line Items]
Weighted average exercise price of warrants		1.44		1.44
Weighted average remaining life of warrants				2 years
Shares issuable under Stock Option Plan, as percent of shares outstanding	25.00%
Stock based compensation expense, stock option		$ 29	$ 52	$ 29	$ 52
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum		1.20%	1.125%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum		1.32%	1.25%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum		159.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum		163.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		7 years	7 years
Before Amendment [Member]
Stockholders Equity Note [Line Items]
Shares issuable under Stock Option Plan	20,000
After Amendment [Member]
Stockholders Equity Note [Line Items]
Shares issuable under Stock Option Plan	6,290

XML

Consolidated Statements of Stockholders' Equity (USD $) In Thousands, except Share data	Total USD ($)	Warrant [Member] USD ($)	Settlement of Advances [Member] USD ($)	Initial Public Offering [Member] USD ($)	Other [Member] USD ($)	Series A Special Warrants [Member] USD ($)	Rights [Member] USD ($)	Oxiquant [Member] USD ($)	Consultants [Member] USD ($)	Financing Warrant [Member] USD ($)	Financing Warrant [Member] February 2007 Financing [Member] USD ($)	Convertible Notes Payable [Member] June 2004 Convertible Notes [Member] USD ($)	Convertible Notes Payable [Member] December 2004 Convertible Notes [Member] USD ($)	Nonredeemable Preferred Stock [Member] USD ($)	Private Placement [Member]	Private Placement [Member] December 2004 Placement [Member] USD ($)	Private Placement [Member] May 2004 Placement [Member] USD ($)	Private Placement [Member] July 2005 Placement [Member] USD ($)	Private Placement [Member] May 2006 Placement [Member] USD ($)	Employees [Member] USD ($)	Cadherin Biomedical Inc. [Member] USD ($)	Common Stock USD ($)	Common Stock Warrant [Member] USD ($)	Common Stock Settlement of Advances [Member] USD ($)	Common Stock Initial Public Offering [Member] USD ($)	Common Stock Other [Member] USD ($)	Common Stock Series A Special Warrants [Member] USD ($)	Common Stock Rights [Member] USD ($)	Common Stock Oxiquant [Member] USD ($)	Common Stock Financing Warrant [Member] February 2007 Financing [Member] USD ($)	Common Stock Financing Warrant [Member] April 2010 Financing [Member]	Common Stock Convertible Notes Payable [Member] June 2004 Convertible Notes [Member] USD ($)	Common Stock Convertible Notes Payable [Member] December 2004 Convertible Notes [Member] USD ($)	Common Stock Private Placement [Member] December 2004 Placement [Member] USD ($)	Common Stock Private Placement [Member] May 2004 Placement [Member] USD ($)	Common Stock Private Placement [Member] July 2005 Placement [Member] USD ($)	Common Stock Private Placement [Member] May 2006 Placement [Member] USD ($)	Common Stock Cadherin Biomedical Inc. [Member] USD ($)	Non-redeemable Preferred Stock of Subsidiary USD ($)	Non-redeemable Preferred Stock of Subsidiary Nonredeemable Preferred Stock [Member] USD ($)	Additional Paid-in Capital USD ($)	Additional Paid-in Capital Warrant [Member] USD ($)	Additional Paid-in Capital Series A Special Warrants [Member] USD ($)	Additional Paid-in Capital Rights [Member] USD ($)	Additional Paid-in Capital Oxiquant [Member] USD ($)	Additional Paid-in Capital Consultants [Member] USD ($)	Additional Paid-in Capital Financing Warrant [Member] USD ($)	Additional Paid-in Capital Financing Warrant [Member] February 2007 Financing [Member] USD ($)	Additional Paid-in Capital Convertible Notes Payable [Member] June 2004 Convertible Notes [Member] USD ($)	Additional Paid-in Capital Convertible Notes Payable [Member] December 2004 Convertible Notes [Member] USD ($)	Additional Paid-in Capital Private Placement [Member] December 2004 Placement [Member] USD ($)	Additional Paid-in Capital Private Placement [Member] May 2004 Placement [Member] USD ($)	Additional Paid-in Capital Private Placement [Member] July 2005 Placement [Member] USD ($)	Additional Paid-in Capital Private Placement [Member] May 2006 Placement [Member] USD ($)	Additional Paid-in Capital Employees [Member] USD ($)	Accumulated Other Comprehensive Income USD ($)	Deficit Accumulated During Development Stage USD ($)	Deficit Accumulated During Development Stage Initial Public Offering [Member] USD ($)	Deficit Accumulated During Development Stage Rights [Member] USD ($)
Begining Balance at Sep. 02, 1996
Issuance of stock (in shares)																						89,000
Net (loss) income	$ (37)																																																								$ (37)
Ending Balance at Jun. 30, 1997	(37)																																																								(37)
Ending Balance (in shares) at Jun. 30, 1997																						89,000
Net (loss) income	(398)																																																								(398)
Ending Balance at Jun. 30, 1998	(435)																																																								(435)
Exchange of Adherex Inc. shares for Adherex Technologies Inc. shares (in shares)																						(89,000)
Issuance of stock (in shares)																						239,000
Issuance of stock	1,615																					1,615
Cumulative translation adjustment	20																																																							20
Net (loss) income	(958)																																																								(958)
Ending Balance at Jun. 30, 1999	242																					1,615																																		20	(1,393)
Ending Balance (in shares) at Jun. 30, 1999																						264,000
Issuance of warrants		255																																								255
Issuance of stock (in shares)																						16,000		16,000
Issuance of stock	793		175																			793		175
Issuance of equity rights	171																																								171
Cancellation of common stock (in shares)																								(7,000)
Cumulative translation adjustment	16																																																							16
Net (loss) income	(1,605)																																																								(1,605)
Ending Balance at Jun. 30, 2000	47																					2,583																			426															36	(2,998)
Ending Balance (in shares) at Jun. 30, 2000																						446,000
Issuance of warrants		1,722				4,335																																				1,722	4,335
Other (in shares)																										5,000
Other					341																					341
Issuance of stock (in shares)																									74,000
Issuance of stock				5,689																					5,727																																	(38)
Conversion of convertible securities (in shares)																							30,000				69,000	4,000
Conversion of convertible securities																							1,977				4,335	171														(1,977)	(4,335)	(171)
Cumulative translation adjustment	182																																																							182
Net (loss) income	(2,524)																																																								(2,524)
Ending Balance at Jun. 30, 2001	9,792																					15,134																																		218	(5,560)
Cumulative translation adjustment	11																																																							11
Net (loss) income	(3,732)																																																								(3,732)
Ending Balance at Jun. 30, 2002	6,071																					15,134																																		229	(9,292)
Begining Balance (in shares) at Jun. 30, 2002																						446,000
Issuance of warrants										53																																					53
Stock options issued									4																																					4
Stock Issued for Acquisitions (in shares)																													446,000
Stock Issued for Acquisitions								11,620																					11,077																543
Equity component of convertible notes	1,058																																								1,058
Exercise of stock options (in shares)																						1,000
Exercise of stock options	4																					4
Distribution to shareholders	(158)																																																								(158)
Stated capital reduction																						(9,489)																			9,489
Cumulative translation adjustment	(159)																																																							(159)
Net (loss) income	(17,795)																																																								(17,795)
Ending Balance at Jun. 30, 2003	698																					16,726																			11,147															70	(27,245)
Ending Balance (in shares) at Jun. 30, 2003																						893,000
Repricing of warrants related to financing									18																																					18
Issuance of warrants										54																																					54
Stock options issued									148																																					148
Equity component of convertible notes	1,983																																								1,983
Issuance of stock (in shares)																																		640,000	259,000
Issuance of stock														1,045		13,830	8,474																	8,053	6,356					1,045											5,777	2,118
Conversion of convertible securities (in shares)																																96,000	60,000
Conversion of convertible securities												1,123	171																			1,216	569																(93)	(398)
Exercise of stock options (in shares)																						1,000
Exercise of stock options	23																					23
Amalgamation of 2037357 Ontario Inc.	(22)																					660																	(1,045)		363
Amalgamation of 2037357 Ontario Inc., shares																						44,000
Cumulative translation adjustment	(219)																																																							(219)
Net (loss) income	(6,872)																																																								(6,872)
Ending Balance at Jun. 30, 2004	20,454																					33,603																			21,117															(149)	(34,117)
Cost related to SEC registration	(493)																					(493)
Stock options issued									39											604																										39									604
Stock Issued for Acquisitions (in shares)																																						37,000
Stock Issued for Acquisitions																					1,252																	1,252
Cumulative translation adjustment	1,392																																																							1,392
Net (loss) income	(6,594)																																																								(6,594)
Ending Balance at Dec. 31, 2004	16,654																					34,362																			21,760															1,243	(40,711)
Ending Balance (in shares) at Dec. 31, 2004																						2,030,000
Financing costs	(141)																					(141)
Stock options issued									276																																					276
Issuance of stock (in shares)																																				337,000
Issuance of stock																		8,134																		7,060																	1,074
Exercise of stock options (in shares)																						1,000
Exercise of stock options	25																					25
Net (loss) income	(13,871)																																																								(13,871)
Ending Balance at Dec. 31, 2005	11,077																					41,306																			23,110															1,243	(54,582)
Ending Balance (in shares) at Dec. 31, 2005																						2,368,000
Stock options issued									100											491																										100									491
Issuance of stock (in shares)																																					431,000
Issuance of stock																			6,040																		5,218																	822
Net (loss) income	(16,440)																																																								(16,440)
Ending Balance at Dec. 31, 2006	1,268																					46,524																			24,523															1,243	(71,022)
Begining Balance (in shares) at Dec. 31, 2006																						2,799,000
Exercise of warrants (in shares)																						116,000
Exercise of warrants	694																					563																			131
Stock options issued									59											2,263																										59									2,263
Issuance of stock (in shares)																														4,209,000
Issuance of stock											23,221																			17,842																		5,379
Net (loss) income	(13,357)																																																								(13,357)
Ending Balance at Dec. 31, 2007	14,148																					64,929																			32,355															1,243	(84,379)
Ending Balance (in shares) at Dec. 31, 2007																						7,124,000
Stock options issued									88											2,417																										88									2,417
Net (loss) income	(13,600)																																																								(13,600)
Ending Balance at Dec. 31, 2008	3,053																					64,929																			34,860															1,243	(97,979)
Ending Balance (in shares) at Dec. 31, 2008																						7,124,000
Stock options issued									10											355																										10									355
Net (loss) income	(3,012)																																																								(3,012)
Ending Balance at Dec. 31, 2009	406																					64,929																			35,225															1,243	(100,991)
Ending Balance (in shares) at Dec. 31, 2009																						7,124,000
Stock options issued									53											2,439																										53									2,439
Issuance of stock (in shares)																															13,337,000
Net (loss) income	(7,824)																																																								(7,824)
Ending Balance at Dec. 31, 2010	(4,926)																					64,929																			37,717															1,243	(108,815)
Ending Balance (in shares) at Dec. 31, 2010																						20,461,000
Stock options issued									20											129																								199		20									129
Issuance of stock (in shares)																												4,697,000
Issuance of stock							(28)																					1,023																															(1,250)
Net (loss) income	4,685																																																								4,685
Ending Balance at Dec. 31, 2011	(120)																					65,952																			38,065															1,243	(105,380)
Ending Balance (in shares) at Dec. 31, 2011																						25,158,000
Stock options issued									152											174																										152									174
Net (loss) income	(5,163)																																																								(5,163)
Ending Balance at Dec. 31, 2012	(4,957)																					65,952																			38,391															1,243	(110,543)
Ending Balance (in shares) at Dec. 31, 2012																						25,158,000
Net (loss) income	(4,108)																																																								(4,108)
Ending Balance at Mar. 31, 2013	(9,065)																					65,952																			38,391															1,243	(114,651)
Ending Balance (in shares) at Mar. 31, 2013																						25,158,000
Stock options issued																				29																																			29
Net (loss) income	6,607																																																								6,607
Ending Balance at Jun. 30, 2013	$ (2,429)																					$ 65,952																			$ 38,420															$ 1,243	$ (108,044)
Ending Balance (in shares) at Jun. 30, 2013																						25,158,000

XML

Significant Accounting Policies

6 Months Ended

Jun. 30, 2013

Significant Accounting Policies [Abstract]

Significant Accounting Policies

2. Significant Accounting Policies

Basis of presentation

The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. GAAP and are the responsibility of the Company’s management. These financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. Accordingly, these unaudited interim consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and notes filed with the Securities and Exchange Commission (“SEC”) in the Company's Annual Report on Form 10-K for the year ended December 31, 2012. The Company's accounting policies are consistent with those presented in the audited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012. These unaudited interim consolidated financial statements have been prepared in U.S. dollars.

Use of estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Significant estimates include certain accruals, valuation of derivative warrant liability and the value of stock based compensation. Actual results could differ from those estimates.

In the opinion of management, these unaudited interim consolidated financial statements include all normal and recurring adjustments, considered necessary for the fair presentation of the Company’s financial position at June 30, 2013, and to state fairly the results for the periods presented. The most significant estimates included in these financial statements are the derivative instruments described in Note 3. There were significant changes in their valuation during the quarter.

Newly Accounting Pronouncements Adopted

In February 2013, the FASB issued ASU No. 2013-02, "Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income" ("ASU 2013-02"), which requires companies to provide information about the amounts reclassified out of AOCI by component. In addition, companies are required to report significant amounts reclassified out of AOCI by the respective line items of net income if the amount reclassified is required to be reclassified to net income in its entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, companies are required to cross-reference to other disclosures that provide additional detail on those amounts. ASU 2013-02 is effective prospectively for reporting periods beginning after December 15, 2012 and has not impacted the Company's consolidated financial condition, results of operations or cash flows.

Cash and cash equivalents

Cash and cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less.The Company places its cash and cash equivalents in investments held by financial institutions in accordance with its investment policy designed to protect the principal investment. At June 30, 2013, the Company had $913 in money market investments, which typically have minimal risk and $94 in cash of which $13 was in Canadian dollars. The Company has not experienced any loss or write down of its money market investments.

XML

Fair Value Measurements

6 Months Ended

Jun. 30, 2013

Fair Value Disclosures [Abstract]

Fair Value Measurements

5. Fair Value Measurements

The Company has adopted the Fair Value Measurements and Disclosure Topic of the FASB. This Topic applies to certain assets and liabilities that are being measured and reported on a fair value basis. The Fair Value Measurements Topic defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosure about fair value measurements. This Topic enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The Topic requires that financial assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

Assets/Liabilities Measured at Fair Value on a Recurring Basis

	Fair Value Measurement at June 30, 2013
	Quoted Price in Active Markets		Significant Other		Significant
	for Identical Instruments		Observable Inputs		Unobservable Inputs
	Level 1		Level 2		Level 3		Total
Assets
Cash & Cash equivalents		94	$	913		-	$	1,007
Liabilities
Derivative liabilities		-		2,678		-		2,678
TOTAL		94	$	3,591		-	$	3,685

The Company's financial instruments include cash and cash equivalents and derivatives. Only cash and cash equivalents and derivatives are carried at their fair value. The derivative liabilities include warrants denominated in a currency other than the Company’s functional currency and options issued to contractors in a currency other than the functional currency of the Company. The warrants are carried at fair value and calculated using the Black-Scholes option pricing model using the following assumptions: expected dividend 0%; risk-free interest rate of 1.21%-1.35%; expected volatility of 148% - 155%; and a 1.83 or 2.75 year remaining life. The options also use the Black-Scholes model with the following assumptions: expected dividend 0%; risk-free interest rate of 1.66%-1.78% expected volatility of 150%-152%; and a 4.4-4.9 year remaining life. The risk free rate was based on Bank of Canada Bond issues of similar term. Expected volatility was estimated by using historical volatility of weekly close share prices for a period equal to the remaining life of the instrument.

XML

Derivative Instruments

6 Months Ended

Jun. 30, 2013

Derivative Instruments [Abstract]

Derivative Instruments

3. Derivative Instruments

Effective January 1, 2009, the Company adopted Accounting Standards Codification (ASC) Topic 815-40, "Derivatives and Hedging" (ASC 815-40). One of the conclusions reached under ASC 815-40 was that an equity-linked financial instrument would not be considered indexed to the entity's own stock if the strike price is denominated in a currency other than the issuer's functional currency. The conclusion reached under ASC 815-40 clarified the accounting treatment for these and certain other financial instruments. ASC 815-40 specifies that a contract would not be treated as a derivative if it met the following conditions: (a) indexed to the Company's own stock; and (b) classified in stockholders' equity in the Company's statement of financial position. The Company's outstanding warrants denominated in Canadian dollars are not considered to be indexed to its own stock because the exercise price is denominated in Canadian dollars and the Company's functional currency is United States dollars. Therefore, these warrants have been treated as derivative financial instruments and recorded at their fair value as a liability. All other outstanding convertible instruments are considered to be indexed to the Company's stock, because their exercise price is denominated in the same currency as the Company's functional currency, and are included in stockholders' equity (deficiency).

The Company's derivative instruments include warrants to purchase 18,035 shares, the exercise prices for which are denominated in a currency other than the Company's functional currency, as follows:

· Warrants to purchase 13,337 shares at CAD $1.44 per whole share that expire on April 30, 2015; and

· Warrants to purchase 4,698 shares exercisable at CAD $1.44 per whole share that expire on March 29, 2016.

These warrants were recorded at their fair value as a liability at issuance and will continue to be re-measured at fair value as a liability at each subsequent balance sheet date. Any change in value between reporting periods will be recorded as unrealized gain/(loss). These warrants will continue to be reported as a liability until such time as they are exercised or expire. The fair value of these warrants is estimated using the Black-Scholes option-pricing model.

As of June 30, 2013, the fair value of the warrants expiring April 30, 2015 and March 29, 2016 was determined to be $1,729 and $898, respectively (December 31, 2012 – warrants expiring April 30, 2015 and March 29, 2016, fair value of $4,698 and $1,847, respectively), and the gain on these warrants for the three months ended June 30, 2013 was $5,286 and $2,147, respectively (For the three months ended June 30, 2012 - warrants expiring April 30, 2015 and March 29, 2016, gain of $513 and $125, respectively.) The six month gain on the warrants expiring April 30, 2015 and March 29, 2016 for the six months ended June 30, 2013 was $2,969 and $949, respectively (For the six months ended June 30, 2012 - warrants expiring April 30, 2015 and March 29, 2016, gain of $2,981 and $946, respectively.)There is no cash flow impact for these derivatives until the warrants are exercised. If these warrants are exercised, the Company will receive the proceeds from the exercise at the current exchange rate at the time of exercise.

Gain/(Loss) on Derivative Instruments	Three months ended June 30, 2013		Three months ended June 30, 2012
Warrants expiring April 30, 2015		5,286		513
Warrants expiring March 29, 2016		2,147		125
Options to contractors		102		7
Gain on Derivative Instruments		7,535		645

Gain/(Loss) on Derivative Instruments	Six months ended June 30, 2013		Six months ended June 30, 2012
Warrants expiring April 30, 2015		2,969		2,981
Warrants expiring March 29, 2016		949		946
Options to contractors		44		44
Gain on Derivative Instruments		3,962		3,971

During the fiscal year ended December 31, 2011, the Company issued 108 options to contractors with a Canadian dollar denominated strike price. Consequently, the Company now has derivatives relating to these options since the strike price is denominated in a currency other than the US dollar functional currency of the Company. While there is an exception to this rule for employees in ASU 2010-13 "Compensation-Stock Compensation (Topic 718):Effect of Denominating the exercise price of a share based payment award in the currency of the market in which the underlying equity security trades", no such exception exists for contractors. These options will be marked to market until the earlier of their expiry or exercise. The fair value of these options at June 30, 2013 was $51 (December 31, 2012 - $95) and the gain for the three and six months ended June 30, 2013 was $102 and $44, respectively (June 30, 2012 – gain of $7 and $44, respectively).

XML

Commitments - Additional information (Details) (USD $)	3 Months Ended		6 Months Ended		202 Months Ended	6 Months Ended		1 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2013 Rostislav Raykov [Member]	Jun. 30, 2013 Robert Andrade [Member]	Feb. 20, 2013 Payment Upon First Commercial Sale Of Sts [Member]	Sep. 26, 2002 Payment Up On Completion Of Phase Iii Clinical Trial [Member]
Expected Future Contract Payments								$ 100,000	$ 500,000
Severance Costs	$ 0	$ 0	$ 0	$ 0	$ 168,000	$ 140	$ 140

XML

Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Common stock, no par value	$ 0	$ 0
Common stock, shares issued	0	25,158
Common stock, shares outstanding	0	25,158

XML

Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2013

Significant Accounting Policies [Abstract]

Basis of presentation

Basis of presentation

The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. GAAP and are the responsibility of the Company’s management. These financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. Accordingly, these unaudited interim consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and notes filed with the Securities and Exchange Commission (“SEC”) in the Company's Annual Report on Form 10-K for the year ended December 31, 2012. The Company's accounting policies are consistent with those presented in the audited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012. These unaudited interim consolidated financial statements have been prepared in U.S. dollars.

Use of estimates

Use of estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Significant estimates include certain accruals, valuation of derivative warrant liability and the value of stock based compensation. Actual results could differ from those estimates.

In the opinion of management, these unaudited interim consolidated financial statements include all normal and recurring adjustments, considered necessary for the fair presentation of the Company’s financial position at June 30, 2013, and to state fairly the results for the periods presented. The most significant estimates included in these financial statements are the derivative instruments described in Note 3. There were significant changes in their valuation during the quarter.

Newly Accounting Pronouncements Adopted

Newly Accounting Pronouncements Adopted

In February 2013, the FASB issued ASU No. 2013-02, "Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income" ("ASU 2013-02"), which requires companies to provide information about the amounts reclassified out of AOCI by component. In addition, companies are required to report significant amounts reclassified out of AOCI by the respective line items of net income if the amount reclassified is required to be reclassified to net income in its entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, companies are required to cross-reference to other disclosures that provide additional detail on those amounts. ASU 2013-02 is effective prospectively for reporting periods beginning after December 15, 2012 and has not impacted the Company's consolidated financial condition, results of operations or cash flows.

Cash and cash equivalents

Cash and cash equivalents

Cash and cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less.The Company places its cash and cash equivalents in investments held by financial institutions in accordance with its investment policy designed to protect the principal investment. At June 30, 2013, the Company had $913 in money market investments, which typically have minimal risk and $94 in cash of which $13 was in Canadian dollars. The Company has not experienced any loss or write down of its money market investments.

XML

Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended		202 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
Operating activities:
Net income/(loss)	$ 6,607	$ (602)	$ 2,499	$ 2,112	$ (106,635)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	0	0	0	0	1,404
Non-cash Cadherin Biomedical Inc. litigation	0	0	0	0	1,187
Unrealized gain on derivative	(7,535)	(645)	(3,962)	(3,971)	(7,219)
Amortization of deferred lease inducements	0	0	0	0	(412)
Unrealized foreign exchange loss	0	0	0	0	36
Loss on impairment of capital assets	0	0	0	0	386
Non-cash severance	0	0	0	0	168
Stock-based compensation - consultants		35		35	1,048
Stock-based compensation - employees	29	17	29	17	10,298
Acquired in-process research and development	0	0	0	0	13,094
Changes in non-cash working capital	10	62	138	96	312
Net cash used in operating activities	(889)	(1,133)	(1,296)	(1,711)	(86,333)
Investing activities:
Purchase of capital assets	0	0	0	0	(1,440)
Disposal of capital assets	0	0	0	0	115
Proceeds from sale of assets	0	0	0	0	24
Release of restricted cash	0	0	0	0	190
Restricted cash	0	0	0	0	(209)
Purchase of short-term investments	0	0	0	0	(22,148)
Redemption of short-term investments	0	0	0	0	22,791
Investment in Cadherin Biomedical Inc.	0	0	0	0	(166)
Acquired intellectual property rights	0	0	0	0	(640)
Net cash used in investing activities	0	0	0	0	(1,483)
Financing activities:
Conversion of long-term debt to equity	0	0	0	0	68
Long-term debt repayment	0	0	0	0	(65)
Capital lease repayments	0	0	0	0	(8)
Issuance of units, net of issue costs	0	0	0	0	86,443
Registration expense	0	0	0	0	(465)
Proceeds from convertible note	0	0	0	0	3,017
Other liability repayments	0	0	0	0	(87)
Financing expenses	0	0	0	0	(544)
Security deposits received	0	0	0	0	35
Proceeds from exercise of stock options	0	0	0	0	51
Net cash provided by financing activities	0	0	0	0	88,445
Effect of exchange rate on cash and cash equivalents					378
(Decrease)/Increase in cash and cash equivalents	(889)	(1,133)	(1,296)	(1,711)	1,007
Cash and cash equivalents - Beginning of period	1,896	4,719	2,303	5,297	0
Cash and cash equivalents - End of period	$ 1,007	$ 3,586	$ 1,007	$ 3,586	$ 1,007

XML

Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 1,007	$ 2,303
Prepaid expenses	20	56
Other current assets	3	6
Total assets	1,030	2,365
Current liabilities:
Accounts payable	716	259
Accrued liabilities	65	423
Derivative liabilities	2,678	6,640
Total liabilities	3,459	7,322
Commitments (see Note 6)
Stockholders' equity:
Common stock, no par value; unlimited shares authorized; 25,158 shares issued and outstanding (2012-25,158)	65,952	65,952
Additional paid-in capital	38,420	38,391
Deficit accumulated during development stage	(108,044)	(110,543)
Accumulated other comprehensive income	1,243	1,243
Total stockholders’ equity (deficiency)	(2,429)	(4,957)
Total liabilities and stockholders’ equity	$ 1,030	$ 2,365

XML

Subsequent Events - Additional information (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012	Aug. 01, 2013 Subsequent Event [Member]
Subsequent Event [Line Items]
Accounts Payable Current	$ 716,000	$ 259,000	$ 490
Accounts Payble Settlement Amount			$ 230

XML

Stockholders' Equity (Summary Of Option Activity) (Details) In Thousands, except Per Share data, unless otherwise specified	6 Months Ended
	Jun. 30, 2013 Stock Option In Canadian Dollars [Member] CAD	Jun. 30, 2013 Stock Option In Us Dollars [Member] USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Number of Options Outstanding at December 31, 2012	4,171	1,327
Number of OptionsGranted	0	35
Number of Options Exercised	0	0
Number of Options Expired	0	0
Number of Options Outstanding at June 30, 2013	4,171	1,362
Weighted-average Exercise Price Outstanding at December 31, 2012	0.78	$ 0.67
Weighted-average Exercise Price Granted	0	$ 0.86
Weighted-average Exercise Price Exercised	0	$ 0
Weighted-average Exercise Price Expired	0	$ 0
Weighted-average Exercise Price Outstanding at June 30, 2013	0.78	$ 0.67

XML

Subsequent Events

6 Months Ended

Jun. 30, 2013

Subsequent Events [Abstract]

Subsequent Events

7. Subsequent Events

On August 1, 2013, Adherex settled a balance of $490 in accounts payables for a total of $230. This settlement is not reflected in the company’s financial statements for the period ending June 30, 2013.

XML

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2013

Stockholders' Equity [Abstract]

Warrants Outstanding to Purchase Common Stock

At June 30, 2013, the Company had the following warrants outstanding to purchase common stock priced in Canadian dollars with a weighted average exercise price of CAD $1.44 and a weighted average remaining life of 2.0 years:

Warrant Description	Common Shares Issuable Upon Exercise of Outstanding Warrants at June 30, 2013		Exercise Price In CAD Dollars		Expiration Date
Investor warrants (1)		13,337	$	1.44	April 30, 2015
Investor warrants (2)		4,698	$	1.44	March 29, 2016
		18,035

Schedule of Share-based Compensation, Stock Options, Activity

The following is a summary of option activity for the six months ended June 30, 2013 for stock options denominated in Canadian dollars:

Options in thousands	Number of Options (thousands)		Weighted-average Exercise Price
Outstanding at December 31, 2012		4,171		CAD $ 0.78
Granted		-		-
Exercised		-		-
Expired		-		-
Outstanding at June 30, 2013		4,171		CAD $ 0.78

The following is a summary of option activity for the six months ended June 30, 2013 for stock options denominated in U.S. dollars:

Options in thousands	Number of Options (thousands)		Weighted-average Exercise Price
Outstanding at December 31, 2012		1,327	$	0.67
Granted		35		0.86
Exercised		-		-
Expired		-		-
Outstanding at June 30, 2013		1,362	$	0.67

XML

Commitments

6 Months Ended

Jun. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

6. Commitments

The Company had no material commitments as of June 30, 2013.Under the service agreement with OCT Group LLC entered in August 2010, the Company was required to make several payments over the course of our Phase II clinical trial in Russia. The payments were made upon the fulfillment of several milestones during the clinical trial including regulatory approval of trial, enrollment of patients and the completion of therapy of patients. The Company amended the agreement in April 2011 and August 2011 for the addition of additional sites for OCT to service during the Phase II clinical trial. The Company amended the agreement in June 2012 for the transition to a paper-based database to be developed by OCT. In addition, the Company amended the agreement on October 29, 2012 for the addition of up to 20 patients to be enrolled. The service agreement with OCT expired on June 30, 2013.

Under the license agreement with Oregon Health & Science University (OHSU) for STS dated February 20, 2013, upon the first commercial sale of STS we may become responsible for a payment to OHSU of up to $0.1 million. Prior to this new license agreement with OHSU, the previous license agreement with OHSU dated September 26, 2002, included that the Company may have become responsible for a payment to OHSU of up to $0.5 million upon the successful completion of the Phase III clinical trial with COG or SIOPEL. The license agreement with OHSU dated September 26, 2002 was terminated on February 20, 2013. Royalty payments are contingent on sales.

In the event of his termination with us other than for cause, the Company will pay Rostislav Raykov $140 in severance. In the event of his termination with us other than for cause, the Company will pay Robert Andrade $140 in severance.

XML

Going Concern

6 Months Ended

Jun. 30, 2013

Going Concern [Abstract]

Going Concern

1. Going Concern

Adherex Technologies Inc. (“Adherex”), a British Columbia corporation together with its wholly-owned subsidiaries Oxiquant, Inc. (“Oxiquant”) and Adherex, Inc., both Delaware corporations, and Cadherin Biomedical Inc. (“CBI”), a Canadian corporation, collectively referred to herein as the “Company”, is a development stage biopharmaceutical company with a portfolio of product candidates under development for use in the treatment of cancer. With the exception of Adherex Inc., all subsidiaries are inactive.

These unaudited interim consolidated financial statements have been prepared using generally accepted accounting principles (“GAAP”) in the United States (“U.S.”) of America that are applicable to a going concern which contemplates that Adherex will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company is a development stage company and during the six months ended June 30, 2013 generated net income of $2,499 which includes an unrealized non-cash gain of $3,962 on derivative liabilities. Cash used in operations in the six months ended June 30, 2013 was $1,296. At June 30, 2013, the Company had an accumulated deficit of $108,045 and had experienced negative cash flows from operations since inception in the amount of $86,333.

These circumstances cast substantial doubt as to the ability of the Company to meet its obligations as they come due and, accordingly, the use of accounting principles applicable to a going concern may not be appropriate. The Company will need to obtain additional funding in the future in order to finance its business strategy beyond the current trials through the issuance of equity, debt or collaboration. If the Company fails to arrange for sufficient capital on a timely basis, it may be required to curtail its business activities until it can obtain adequate financing.

If we cannot obtain adequate funding in the future, we might be required to further delay, scale back or eliminate certain research and development studies, consider business combinations or even shut down some, or all, of our operations. It is management’s intent to continue operating the company until the results of the Phase III Children’s Oncology Group STS trial is finalized, which is expected to occur in the third quarter of 2013. The results of this trial will determine whether the company has any strategic alternative to an orderly wind-down.

These unaudited financial statements do not reflect the potentially material adjustments in the carrying values of assets and liabilities, the reported expenses, and the balance sheet classifications used, that would be necessary if the going concern assumption were not appropriate.

XML

Significant Accounting Policies - Additional Information (Details)	Jun. 30, 2013 USD ($)	Jun. 30, 2013 CAD
Summary Of Significant Accounting Policies [Line Items]
Money market investments	$ 913
Cash	$ 94	13

XML

Derivative Instruments (Tables)

6 Months Ended

Jun. 30, 2013

Derivative Instruments [Abstract]

Gain Loss on Derivative Instruments

Gain/(Loss) on Derivative Instruments	Three months ended June 30, 2013		Three months ended June 30, 2012
Warrants expiring April 30, 2015		5,286		513
Warrants expiring March 29, 2016		2,147		125
Options to contractors		102		7
Gain on Derivative Instruments		7,535		645

Gain/(Loss) on Derivative Instruments	Six months ended June 30, 2013		Six months ended June 30, 2012
Warrants expiring April 30, 2015		2,969		2,981
Warrants expiring March 29, 2016		949		946
Options to contractors		44		44
Gain on Derivative Instruments		3,962		3,971

XML

Shareholders' Equity (Warrants Outstanding to Purchase Common Stock) (Details)	6 Months Ended
	Jun. 30, 2013		Dec. 31, 2012	Jun. 30, 2003
Class of Warrant or Right [Line Items]
Common shares issuable upon exercise of outstanding warrants	18,035
Investor warrants expiring April 30, 2015 [Member]
Class of Warrant or Right [Line Items]
Common shares issuable upon exercise of outstanding warrants	13,337	[1]		13,337
Exercise Price In CAD Dollars	1.44	[1]
Expiration Date	Apr. 30, 2015	[1]
Investor warrants expiring March 29, 2016 [Member]
Class of Warrant or Right [Line Items]
Common shares issuable upon exercise of outstanding warrants	4,698	[2]	4,698
Exercise Price In CAD Dollars	1.44	[2]		1.44
Expiration Date	Mar. 29, 2016	[2]

[1] On April 30, 2010, the Company announced that it had completed a first closing of a non-brokered private placement ("Private Placement") of 240,066 units, at a price of CAD $0.03 per unit for net proceeds of CAD$7,200. Each unit consisted of one common share and one common share purchase warrant (a "Warrant"). As a result of the Share Consolidation in 2011, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date.

[2] On March 29, 2011, the Company announced that it had completed a non-brokered rights offering of 84,559 units, at a price of CAD $0.03 per unit for total net proceeds of $2,547. Each unit consisted of one common share and one common share purchase warrant (a “Warrant”). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD $1.44 per whole share for a period of five years from the issue date.

XML

Derivative Instruments (Gain Loss on Derivative Instruments) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended		202 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) on Derivative Instruments	$ 7,535	$ 645	$ 3,962	$ 3,971	$ 7,219
Warrants expiring April 30, 2015
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) on Derivative Instruments	5,286	513	2,969	2,981
Warrants expiring March 29, 2016
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) on Derivative Instruments	2,147	125	949	946
Options to Contractors [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) on Derivative Instruments	$ 102	$ 7	$ 44	$ 44

XML

Document And Entity Information	6 Months Ended
	Jun. 30, 2013	Aug. 10, 2013
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q2
Trading Symbol	ADHXF
Entity Registrant Name	ADHEREX TECHNOLOGIES INC
Entity Central Index Key	0001211583
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		25,157,861

XML

Derivative Instruments - Additional Information (Details) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended	202 Months Ended	3 Months Ended			6 Months Ended					3 Months Ended			6 Months Ended					3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Jun. 30, 2013	Jun. 30, 2013 Investor warrants expiring April 30, 2015 [Member]		Jun. 30, 2012 Investor warrants expiring April 30, 2015 [Member]	Jun. 30, 2013 Investor warrants expiring April 30, 2015 [Member]		Jun. 30, 2012 Investor warrants expiring April 30, 2015 [Member]	Dec. 31, 2012 Investor warrants expiring April 30, 2015 [Member]	Jun. 30, 2003 Investor warrants expiring April 30, 2015 [Member]	Jun. 30, 2013 Investor warrants expiring March 29, 2016 [Member]		Jun. 30, 2012 Investor warrants expiring March 29, 2016 [Member]	Jun. 30, 2013 Investor warrants expiring March 29, 2016 [Member]		Jun. 30, 2012 Investor warrants expiring March 29, 2016 [Member]	Dec. 31, 2012 Investor warrants expiring March 29, 2016 [Member]	Jun. 30, 2003 Investor warrants expiring March 29, 2016 [Member]	Jun. 30, 2013 Options to Contractors [Member]	Jun. 30, 2012 Options to Contractors [Member]	Jun. 30, 2013 Options to Contractors [Member]	Jun. 30, 2012 Options to Contractors [Member]	Dec. 31, 2011 Options to Contractors [Member]
Derivative [Line Items]
Common shares issuable upon exercise of outstanding warrants	18,035		18,035			18,035	13,337	[1]		13,337	[1]			13,337	4,698	[2]		4,698	[2]		4,698
Warrant exercise price							1.44	[1]		1.44	[1]				1.44	[2]		1.44	[2]			1.44
Expiration Date										Apr. 30, 2015	[1]							Mar. 29, 2016	[2]
Fair value of warrants							$ 1,729			$ 1,729			$ 4,698		$ 898			$ 898			$ 1,847
Gain/(Loss) on Derivative Instruments	7,535,000	645,000	3,962,000	3,971,000		7,219,000	5,286,000		513,000	2,969,000		2,981,000			2,147,000		125,000	949,000		946,000			102,000	7,000	44,000	44,000
Rights offered for each common shares held																											108
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value			$ 51		$ 95

[1] On April 30, 2010, the Company announced that it had completed a first closing of a non-brokered private placement ("Private Placement") of 240,066 units, at a price of CAD $0.03 per unit for net proceeds of CAD$7,200. Each unit consisted of one common share and one common share purchase warrant (a "Warrant"). As a result of the Share Consolidation in 2011, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date.

[2] On March 29, 2011, the Company announced that it had completed a non-brokered rights offering of 84,559 units, at a price of CAD $0.03 per unit for total net proceeds of $2,547. Each unit consisted of one common share and one common share purchase warrant (a “Warrant”). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD $1.44 per whole share for a period of five years from the issue date.